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ABSTRACT 
During hydrolysis of bovine milk caseins, cell envelope-associated proteinases (CEPs) of lactic 
acid bacteria (LAB) may be able to produce hydrolysates that possess in vitro 
immunomodulatory activity. We studied the proteolytic activity against bovine milk caseins 
exerted by specific strains of LAB selected on the basis of a preliminary genomic screening for 
the presence of CEPs. The tested strains demonstrated diverse hydrolytic ability against 
different casein fractions, αS1- and β-casein in particular. The 3 kDa-ultrafiltered casein 
hydrolysates (CHs), produced after digestion with proteinases of Lactobacillus acidophilus 
ATCC 4356 and Lactococcus lactis subsp. lactis GR5 demonstrated immunomodulatory 
activity in vitro by significantly decreasing the basal NF-κB activity in recombinant Caco-2 cell 
layers. Both the strains digested β-casein mostly. However, in the case of Lactobacillus 
helveticus MIMLh5, the investigation proved that the immunomodulatory activity of obtained 
CH was comparable to the one exerted by bacteria themselves (in the absence of caseinate) and 
therefore, was not due to the presence of casein-derived peptides. Indeed, the surface layer (S-
layer) protein of L. helveticus MIMLh5 was identified as a molecule responsible for the 
immunomodulation. Overall, these results emphasize the importance of this bacterial cell-
derived protein while evaluating the immunological activity of CHs, and it underlines the 
necessity to remove such molecule in order to properly assess the bioactivity of CHs deriving 
from the proteolytic activity of LAB. 
The second part of the research was focussed on the selection of surface layer (S-layer)-specific 
single-chain variable fragment antibodies (scFvs), a new powerful tool for the study of the S-
layer of L. helveticus MIMLh5, the immunologically active protein, and for its identification in 
milk-derived products containing L. helveticus as a starter or non starter LAB. In this study, a 
mix of two human synthetic phage displayed libraries (protein-directed and hapten-directed) 
was used to select scFvs against L. helveticus MIMLh5 S-layer protein. After three rounds of 
panning, four monoclonal scFv binders capable of binding to the L. helveticus MIMLh5 S-layer 
protein and one capable of binding not only to the mentioned protein, but also to the S-layer 
protein of L. helveticus ATCC 15009, which is different only in five amino acids, were 
obtained. All five identified novel anti-S-layer scFvs were expressed in Escherichia coli XL1-
Blue, and their basic characterisation was performed. Anti-S-layer-scFv PolyH4 was used to 
develop an assay, based on Western blot analysis, for detection of the S-layer protein in Grana 
Padano samples. These results showed promising applications of the method for the detection of 
the S-layer protein in food matrices. 
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RIASSUNTO 
Composti bioattivi in prodotti derivati dal latte: idrolizzati batterici di 
caseina immunomodulanti e strumenti per l’identificazione di una proteina 
batterica con proprietà immunogeniche 
Durante l’idrolisi delle caseine del latte bovino, le proteinasi della parete cellulare (CEP) di 
alcuni batteri lattici (LAB) possono produrre idrolizzati in grado di esplicare in vitro attività 
immunomodulante. In questo lavoro, è stata studiata l’attività proteolitica a carico delle caseine 
del latte bovino esercitata da specifici ceppi di LAB selezionati sulla base di un preliminare 
screening genomico per la presenza di CEP. I ceppi testati hanno evidenziato una diversa 
capacità idrolitica nei confronti delle diverse frazioni caseiniche, αS1- e β- in particolare. Gli 
ultrafiltrati a 3 kDa degli idrolizzati caseinici (CH) prodotti dopo digestione con proteinasi di 
Lactobacillus acidophilus ATCC 4356 e Lactococcus lactis subsp. lactis GR5 hanno 
evidenziato attività immunomodulante in vitro risultando capaci di ridurre l’attività basale di 
NF-κB nelle cellule ricombinanti Caco-2. Entrambi i ceppi hanno evidenziato una prevalente 
azione idrolitica a carico della β-caseina. Tuttavia, nel caso di Lactobacillus helveticus 
MIMLh5, lo studio ha dimostrato che l’attività immunomodulante del relativo CH era 
paragonabile a quella esercitata dai batteri stessi (in assenza di caseina) e, quindi, non legata 
alla presenza di peptidi originanti dalla proteolisi della caseina. In particolare, la proteina di 
superficie (l’S-layer) di L. helveticus MIMLh5 è stata identificata come la molecola 
responsabile dell’attività immunomodulante del CH. Questi risultati sottolineano l’importanza 
di questa proteina di origine batterica durante la valutazione della attività immunologica di CH 
ed evidenziano la necessità di eliminare tale molecola per valutare correttamente la bioattività 
di CH derivati dall’azione proteolitica di LAB. 
La seconda parte della ricerca è stata focalizzata sulla selezione di anticorpi fagici (single-chain 
variable fragment, scFv) specifici per l’S-layer di L. helveticus MIMLh5: per il suo studio e per 
la sua identificazione nei prodotti lattiero-caseari contenenti L. helveticus come colture starter o 
non-starter LAB. Nel dettaglio, in questo studio due librerie sintetiche umane di fagi (proteine-
diretti e aptene-diretti) sono state utilizzate per selezionare scFvs specifici per la proteina S-
layer di L. helveticus MIMLh5. Dopo tre turni di panning, sono stati identificati quattro 
anticorpi monoclonali scFv in grado di riconoscere la proteina S-layer di L. helveticus 
MIMLh5, ed uno in grado di riconoscere anche l’S-layer del ceppo ATCC 15009, proteina che 
si differenzia da quella del ceppo MIMLh5 per soli cinque aminoacidi. I cinque scFvs anti-S-
layer sono stati espressi in Escherichia coli XL1-Blue ed è stata effettuata la loro 
caratterizzazione di base. Uno di essi (PolyH4) è stato utilizzato per sviluppare un test (sulla 
base di Western blot) per rilevare questa proteina in campioni di Grana Padano. I risultati 
ottenuti evidenziano promettenti applicazioni del metodo per il rilevamento della proteina S-
layer in matrici alimentari. 
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PREFACE 
There has been increased interest in the study of the relationship between nutrition and 
immunity due to the hypothesis that consumption of certain foods may reduce susceptibility for 
the establishment and/or progression of immunological diseases (Sandré et al., 2001). In the last 
decade, the interest in food-derived bioactive peptides has greatly increased (Korhonen & 
Pihlanto, 2006; Hartmann & Meisel, 2007; Phelan et al., 2009a). It is well documented that 
microbiological proteolysis of food proteins (milk proteins being the most widely studied) can 
yield physiologically important bioactive peptides (Hayes et al., 2007a; Korhonen, 2009). 
Bovine milk contains a number of potent immunoregulatory peptides that affect the immune 
system via cellular functions and there is great interest in the immunomodulatory properties of 
casein hydrolysates (CHs) (Migliore-Samour et al., 1989; Sandré et al., 2001; Jing & Kitts, 
2004; Bennett et al., 2005; Phelan et al., 2009b). 
Caseins are the most abundant milk proteins, which constitute the 78 % of total bovine milk 
protein content (Gagnaire et al., 2009). Enzymatic proteolysis of caseins yields many different 
bioactive peptides. A number of these peptides have been identified in milk CHs and fermented 
dairy products, as reviewed in a series of recent papers (Ferranti et al., 2004; Rowan et al., 
2005; Hayes et al., 2007a, 2007b; Jensen et al., 2009; Korhonen, 2009; Phelan et al., 2009a, 
2009b). They have been shown to exert both functional and physiological roles in vitro and in 
vivo, and because of this they are of particular interest for food science and nutrition 
applications. Biological activities associated with such peptides include: immunomodulatory, 
cytomodulatory, hypotensive, antimicrobial, mineral binding, antioxidant, antithrombotic along 
with opioid agonist and antagonist activities (Gill et al., 2000; Korhonen & Pihlanto, 2006; 
Korhonen, 2009; Phelan et al., 2009a). 
These milk casein-derived biologically active peptides are inactive within the sequence of a 
parent protein, but can be released during gastrointestinal digestion, food processing and 
fermentation. The latter comprehends the hydrolysis by proteolytic starter or non-starter 
microorganisms such as lactic acid bacteria (LAB) (Phelan et al., 2009a; Tellez et al., 2010, 
2011). 
Therefore, the first part of this PhD research was directed towards the investigation of the 
immunomodulatory activity of bovine casein hydrolysates produced after digestion with 
proteinases of LAB. 
 
Many LAB have a complex proteolytic system capable of degrading caseins (Jensen et al., 
2009; Sadat-Mekmene et al., 2011) and thus not only having a strong impact on texture and 
flavour of cheese in its production chain (Oberg et al., 1991; Smit et al., 2005), but also 
producing bioactive peptides including those with immunomodulatory properties (Matar et al., 
2001; LeBlanc et al., 2002; LeBlanc et al., 2004; Tellez et al., 2010, 2011). On the other hand, 
LAB such as Lactobacillus helveticus, a thermophilic homofermentative LAB traditionally used 
in cheese manufacture (Fortina et al., 1998; Gatti et al., 2004; Jensen et al., 2009), can exert 
their bioactive abilities by themselves, influencing the host’s immune system (Vinderola et al., 
2005; Galdeano et al., 2007; Timmerman et al., 2007; Lebeer et al., 2008; Guglielmetti et al., 
2010; O’Flaherty & Klaenhammer, 2010). 
It was demonstrated that surface-located molecules, such as heat-shock protein rGroEL 
(Bergonzelli et al., 2006) and surface layer (S-layer) protein (the most abundant bacterial cell 
wall protein, Beganović et al., 2011; Taverniti & Guglielmetti, 2011; Taverniti et al., 
manuscript in preparation), contribute to this activity. Thus, in the light of immunomodulation, 
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the presence of starter and non-starter bacterial cultures should be considered in fermented milk 
products while evaluating their immunomodulatory properties. Furthermore, the necessity to 
have tools for the study of the immunologically active S-layer protein and for its identification 
in milk-derived products containing L. helveticus as a starter or non starter LAB appeared. 
Therefore, the second part of this PhD research was focussed on the development of protein-
specific binders by increasingly important phage display technology (Willats, 2002; Bradbury 
& Marks, 2004; Kehoe & Kay, 2005; Bradbury et al., 2011), a new powerful tool for the study 
of L. helveticus S-layer protein and for its identification in milk-derived products containing L. 
helveticus. 
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1.1 STATE OF THE ART 
1.1.1 Biologically active peptides: the definition 
Bioactive peptides are described as ‘food-derived components (native or generated) that in 
addition to their nutritional value, exert a physiological effect in the body’ (Vermeirssen et al., 
2004). The definition of bioactive peptides include peptides generated from food, which can 
affect one or more biological processes causing a measurable effect on the functions and 
conditions of our body and, ultimately, on health. This definition implies the exclusion of 
peptides with toxic and allergenic effects (Schrezenmeir et at., 2000). 
Today, milk proteins are considered the most important source of bioactive peptides and an 
increasing number of bioactive peptides have been identified in milk protein hydrolysates and 
fermented dairy products. Bioactive peptides derived from milk proteins offer a promising 
approach for the promotion of health by means of a tailored diet and provide interesting 
opportunities to the dairy industry for expansion of its field of operation (Nagpal et al., 2011). 
1.1.2 Production mechanisms of biopeptides: focus on the proteolytic system action of 
LAB 
Milk proteins may contain several biologically active peptides with sizes varying from 2 to 40 
amino acids (Korhonen, 2009; Phelan et al., 2009a). They are inactive within the sequence of a 
parent protein, but can be released during an enzymatic pre-digestion: (i) gastrointestinal 
digestion: hydrolysis with proteolytic enzymes secreted into the gastrointestinal tract such as 
pepsin and chymotrypsin, (ii) food processing: industrial food manufacturing processes, 
including biotransformation with isolated enzymes, and (iii) fermentation: microbial enzymes 
expressed by microorganisms of the intestinal and food microbiota (Möller et al., 2008; 
Korhonen, 2009). 
A large variety of LAB are widely used as starters to produce fermented dairy products. They 
are quite fastidious microorganisms and require an exogenous source of amino acids or peptides 
for optimal growth. As milk is poor in these low-molecular-weight compounds, its growth 
largely depends on their proteolytic system to achieve hydrolysis of caseins into peptides and 
amino acids (Thomas & Pritchard, 1987). The enzymes involved in milk protein degradation 
are: (i) cell envelope proteinases (CEPs), and (ii) intracellular peptidases (Thomas & Pritchard, 
1987). CEPs are the key enzymes of this process since they are the only enzymes responsible 
for the first step of milk casein breakdown into oligopeptides (Siezen, 1999). The latter are then 
transported into the bacteria by a transport system for amino acids, and di-, tri- and 
oligopeptides and further degraded by a complex set of intracellular peptidases (Christensen et 
al., 1999). 
Moreover, CEPs of intestinal microbiota achieve hydrolysis of caseins into peptides with 
biological activities (Hayes et al., 2007a, 2007b). Also in the case of immunomodulatory 
peptides, milk fermentation contributes to the generation of fermented milk with potential 
immunological activity. Despite detailed knowledge of the proteolytic systems of LAB as 
outlined above, information on the production of bioactive peptides through milk fermentation 
and the specific proteinases responsible for bioactive peptide release during dairy fermentation 
is lacking, with only a few reports available (Hayes et al., 2007a) 
The cell wall proteinase of Lactococcus lactis was shown to in vitro liberate oligopeptides from 
β- and α-caseins, which contain amino acid sequences present in casomorphins, casokinines, 
and immunopeptides (Meisel & Bockelmann, 1999). The further degradation of these peptides 
by endopeptidases and exopeptidases of LAB could lead to the liberation of bioactive peptides 
in fermented milk products. Algaron et al. (2004) fermented milk with mutant L. lactis strains 
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lacking either aminopeptidase N, PepX or tripeptidase to test their ability to form peptides with 
anti-hypertensive or immunomodulatory activities, and to relate the resultant bioactivity to a 
specific mutation. Authors reported that, in some cases, the modified proteolytic system of L. 
lactis gave rise to a significant difference in the mixture of peptides produced during milk 
fermentation, indicating that the specific peptidase activity of LAB affects the bioactive nature 
of the peptides produced. 
In Streptococcus thermophilus, the presence of a CEP, PrtS, is less common than in L. lactis. In 
S. thermophilus, high CEP activities are associated with high milk-acidifying capacities 
(Shahbal et al., 1991). Strain CNRZ 385 of this species was first characterised by its rapid 
growth and high acidification rate in milk (Shahbal et al., 1991). This rapid growth was 
correlated with the presence of high proteinase activity associated with the cell wall of S. 
thermophilus strains. Thus, the main role of PrtS was concluded to concern the amino acid 
supply to the cell via casein hydrolysis. This proteinase was later purified and characterised 
biochemically as well as genetically (Fernandez-Espla et al., 2000). In addition, S. thermophilus 
cell wall proteinases were proposed be involved in the development of dairy product health 
properties via bioactive peptide production (Fernandez-Espla et al., 2000). However, no direct 
experimental data exist up to date. MacDonald et al. (1994) and Ganjam et al. (1997) 
demonstrated that bioactive peptides present in yoghurt fermented with S. thermophilus and 
Lactobacillus delbrueckii subsp. bulgaricus, decreased cell proliferation of IEC-6 or Caco-2 
human intestinal epithelial cell lines, which may explain, at least partially, why consumption of 
yoghurt has been associated with a reduced incidence of colon cancer. De Simone and 
collaborators (De Simone et al., 1986) tested interferon γ production of human peripheral blood 
lymphocytes in response to filtered yoghurt devoid of microorganisms, which lets the 
assumption that the immunomodulatory activity is independent from the presence of living 
microorganisms. 
In general, L. helveticus is known to have high proteolytic activity, causing the release of 
oligopeptides from digestion of milk proteins (Lozo et al., 2011; Sadat-Mekmene et al., 2011). 
Laffineur and colleagues (1996) showed that β-casein, fermented with L. helveticus, modulates 
lymphocyte proliferation in vitro. The same bacterial species, selected for the ability to produce 
fermented milk with high ACE-inhibitory activity, produces a fermented milk with 
immunomodulatory properties. Rachid et al. (2006) demonstrated that the administration of 
milk fermented with L. helveticus decreases the growth rate of tumours in a murine model for 
mammary carcinoma. In addition, LeBlanc et al. (2002) used the strain L. helveticus R389 to 
ferment milk. The fermented milk was administered to mice with fibrosarcoma, resulting in a 
decrease of tumour size. Moreover, Matar and colleagues (2001) tested the L. helveticus R389 
non-proteolytic variant for the ability to produce peptides with immunomodulatory activities. 
They reported that protease-deficient variant of L. helveticus R389 failed to induce a general 
activation of the immune system, demonstrating the importance of the CEP activity of the strain 
in the production of peptides with investigated biological activity. 
Milk fermented by L. helveticus not only demonstrated anti-tumoural properties but also 
induced the total antibody production against E. coli O157:H7 in mice infected with this 
pathogen (LeBlanc et al., 2002; LeBlanc et al., 2004). 
Besides the L. helveticus, other LAB were demonstrated to produce milk protein hydrolysates 
with immunomodulatory properties. In fact, milk fermented with Lactobacillus paracasei was 
shown to produce peptides from β-lactoglobulin that stimulate IL-10 production and depress the 
lymphocyte proliferation (Prioult et al., 2004). Sütas and co-workers (1996a, 1996c) 
demonstrated that caseins hydrolysed by Lactobacillus casei GG and digestive enzymes 
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generated compounds with suppressive effects on human T lymphocyte activation, modulating 
IL-2 expression. 
The immunomodulatory activity is independent from the presence of living L. helveticus, as 
demonstrated by LeBlanc and collaborators (2004) who examined the antibody production after 
E. coli O157:H7 infection following the administration of a cell-free supernatant from L. 
helveticus fermented milk. They found that the increased antibody production is not related to 
viable microorganism. More recently, Vinderola et al. (2007) showed that the supernatant of 
fermented milk cultured with L. helveticus increased the immune response independently from 
the presence of lactobacilli. 
Undoubtedly, identification of the links between the proteolytic machinery of cultures used in 
dairy fermentation and resulting bioactivity profiles of milk will benefit the development of 
‘designer’ milk fermentations with specific, tailored and proven health promoting compounds 
targeted at niche sections of the food and possibly pharmaceutical industries (Hayes et al., 
2007a). 
1.1.3 Accessibility of biopeptides by human host 
Only some of the generated biopeptides can cross the intestinal barrier (Hara et al., 1984) and 
reach the target while maintaining their functionality. These peptides have to be small 
(maximum 3 amino acids) in order to cross the enterocyte barrier and must be able to resist 
complete digestion by peptidases found in the cytoplasm of enterocytes. The resistance to these 
enzymes is conferred by the presence in the amino acid sequence residues of proline (Pro), a 
sterically bulky amino acid that makes difficult the access of the peptide bond for hydrolytic 
enzymes (Korhonen & Pihlanto, 2006). An example is the hypotensive tripeptide Val-Pro-Pro, 
whose target is the angiotensin converting enzyme (ACE). It was demonstrated that this peptide 
is able to cross the Caco-2 cell layer in significant quantities, mainly through a paracellular 
diffusion mechanism (Satake et al., 2002). A different mode of transport has been demonstrated 
for tripeptide Lys-Pro-Val, derived from α-melanocyte-stimulating hormone (α-MSH), which 
is able to inhibit the transcriptional activity of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB) in Caco-2 cells in the presence of a transporter of small peptides, 
called hPepT1, expressed on the apical membrane of intestinal cells (Dalmasso et al., 2008), 
suggesting that the mechanism of action of bioactive peptides may involve intracellular target. 
Peptides with dimensions that do not allow absorption through the intestinal barrier, may act 
only inside the lumen, where they can modulate the activity of receptors located on the apical 
membrane of enterocytes or be “sampled” by dendritic cells, which are in close contact with the 
lamina propria of the intestine (Rescigno et al., 2001). 
1.1.4 Milk protein hydrolysates as a source of biologically active peptides 
The rich source of proteins and bioactive peptides is represented by milk and its derivatives, by 
virtue of its role in health protection of a newborn mammal and in the development of his 
immunity (Tsopmo et al., 2009; Szwajkowska et al., 2011). The milk is constituted by a high 
protein content, represented by 78 % of the different casein isoforms (αS1, αS2, β and κ; 
Gagnaire et al., 2009); the rest part is constituted of whey proteins (mainly β-lactoglobulin and 
α-lactalbumin), growth factors, lactoferrin, immunoglobulins and other proteins (Table 1.1.1). 
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Table 1.1.1. Concentration and biological activity of major bovine milk proteins (adapted from 
Mills et al., 2011). 
Protein Concentration 
(g L-1) 
Function 
Total caseins 26.0 Ion carrier (Ca, PO4, Fe, Zn, Cu), precursor of 
bioactive peptides  
α-caseins 13.0 Precursor of bioactive peptides 
β-caseins 9.3 Precursor of bioactive peptides 
κ-casein 3.3 Precursor of bioactive peptides 
Total whey protein 6.3 Anticarcinogenic, weight management 
β-Lactoglobulin 3.2 Retinol carrier, binding fatty acids, possible 
antioxidant 
α-Lactalbumin 1.2 Lactose synthesis in mammary gland, Ca carrier, 
immunomodulation 
Immunoglobulins 
(A, M, and G) 
0.7 Immune protection 
Serum albumin 0.4  
Lactoferrin 0.1 Antimicrobial, antioxidative, immunomodulation, iron 
absorption 
Lactoperoxidase 0.003 Antimicrobial 
Lysozyme 0.0004 Antimicrobial, synergistic effect with 
immunoglobulins and lactoferrin 
Miscellaneous 0.8  
Proteose–peptone 1.2 Function unknown, but precursor of bioactive protein 
and peptide in vitro 
Glycomacropeptide 1.2 Antiviral, bifidogenic 
 
A variety of milk protein-derived biologically active peptides have been shown to exert both 
functional and physiological roles in vitro and in vivo, and because of this they are of particular 
interest for food science and nutrition applications. Biological activities associated with such 
peptides include: antibacterial, hypotensive, immunomodulatory, mineral binding, 
antithrombotic along with opioid agonist and antagonist activities (Korhonen & Philanto, 2006; 
Phelan et al., 2009a, 2009b). 
The milk protein-derived bioactive peptides can be used in production of functional foods, 
foods with scientifically proved beneficial properties. In recent years, the market demand for 
these products has increased, especially in Europe, Japan and Australia (Hilliam, 2003). The 
development and marketing of functional foods requires not only understanding of the detailed 
mechanisms of action and possible side effects, but also aspects related to the technological and 
industrial-scale production. 
1.1.5 Casein-derived biopeptides: focus on peptides displaying immunomodulatory 
activity 
Casein is the main proteinaceous component of milk. Formerly the main physiological role of 
casein in the milk system was widely accepted to be a source of amino acids required by growth 
of the neonate. However, the dominant physiological feature of the casein micelle system was 
later proven to be the prevention of pathological calcification of the mammary gland (Holt, 
1997). While no specific physiological property has been proposed for the whole casein system 
(or its individual fractions), various peptides hidden (or inactive) in the amino-acid sequence 
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have been the subject of increasingly intense studies (Phelan et al., 2009a; Silva & Malcata, 
2005). 
A number of potentially immunoregulatory peptides were identified encrypted in caseins (Table 
1.1.2). 
Table 1.1.2. Immunomodulatory peptides derived from milk caseins (adapted from Silva & 
Malcata, 2005, Hayes et al., 2007b, and Nagpal et al., 2011). 
Precursor 
protein Fragment Peptide sequence 
Name Reference 
αS1-casein 
(bovine) 
1–23 RPKHPIKHQGLPQE
VLNENLLRF 
isracidin Lahov & Regelson, 1996 
Minkiewicz et al., 2000 
 23–34 FFVAPFPEVPGK  Maruyama et al., 1987 
Jollés et al., 1992 
 90–96 RYLGYLE  Migliore-Samour et al., 
1989 
Elitsur & Luk, 1991  
 90–95 RYLGYL  Migliore-Samour et al., 
1989 
Elitsur & Luk, 1991 
 194–199 TTMPLW α-caso 
kinin-6 
Parker et al., 1984 
Migliore-Samour & Jollés, 
1988 
Hernandez-Ledesma et al., 
2004 
αS2-casein 
(bovine) 
1–32 KNTMEHVSSSEESII
SQETYKQEKNMAI
NPSK 
 Coste et al., 1992 
Hata et al., 1999 
Dionysius et al., 2000 
β-casein 
(bovine) 
1–28 RELEELNVPGEIVE
SLSSSEESITRINK 
 Coste et al., 1992 
Hata et al., 1999 
Dionysius et al., 2000 
 60–66 YPFPGPI β-caso 
morphin-7 
Maruyama et al., 1987 
Elitsur & Kuk, 1991 
Kayser & Meisel, 1996 
 63–68 PGPIPN  Parker et al., 1984 
Migliore-Samour & Jollés, 
1988 
Coste et al., 1992 
Fiat et al., 1993 
Dionysius et al., 2000 
 191–193 LLY  Parker et al., 1984 
Migliore-Samour & Jollés, 
1988 
Coste et al., 1992 
Fiat et al., 1993 
Dionysius et al., 2000 
 191–209 LLYQEPVLGPVRGP
FPIIV 
 Coste et al., 1992 
 193–202 YQQPVLGPVR β-caso 
kinin-10 
Maruyama et al., 1987 
Kayser & Meisel, 1996 
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Precursor 
protein Fragment Peptide sequence 
Name Reference 
 193–209 YQEPVLGPVRGPFP
IIV 
 Minkiewicz et al., 2000 
Sandré at al., 2001 
 145–160 
 
143–154 
145–154 
192–202 
HQPHQPLPPTVMFP
PQ 
WMHQPHQPLPPT 
HQPHQPLPPT 
LYQEPVLGPVR 
 Tellez et al., 2010 
Tellez et al., 2011 
β-casein 
(human) 
54–59 VEPIPY  Parker et al., 1984 
Migliore-Samour et al., 
1989 
Coste et al., 1992 
κ-casein 
(bovine) 
38–39 YG  Kayser & Meisel, 1996 
 106–169 MAIPPKKNQDKTEI
PTINTIASGEPTSTP
TTEAVESTVATLED
SPEVIESPPEINTVQ
VTSTAV 
Glycomac- 
ropeptide 
Otani & Hata, 1995 
Otani et al., 1995 
 
These milk casein-derived immunomodulatory peptides have been shown to modulate various 
aspects of immune function (Gill et al., 2000). 
Immunomodulatory casein-derived (and in general milk-derived) peptides may contribute to the 
overall immune response and may improve the immune system function. It was suggested that 
casein-derived peptides are involved in the stimulation of the newborn’s immune system and 
probably even have a direct effect on the resistance to bacterial and viral infection of adult 
humans (Migliore-Samour et al., 1989). 
The evaluation of immunomodulatory activity of casein-derived immunoactive peptides was 
made by measuring the proliferation of lymphocytes, the secretion of immunoglobulin (Ig), IgA 
in particular, the phagocytic activity of macrophages and the effect on cytokine expression. 
Casein-derived peptides showed the ability to modulate the proliferation of human lymphocytes 
(Möller et al., 2008). It was manifested that peptides derived from whole casein or αS1-casein 
limit the proliferation of human lymphocytes, whereas those derived from β- and κ-casein have, 
generally, the opposite effect (Korhonen & Philanto, 2003a, 2003b). 
It was also demonstrated that peptides derived from αS1-, β- and κ-casein have been shown to 
both stimulate and suppress lymphocyte proliferation (Migliore-Samour & Jollés, 1988; Elitsur 
& Luk, 1991; Otani & Hata, 1995; Sütas et al., 1996a, 1996b, 1996c). Certain peptides derived 
from αS1-casein and β-casein have been reported to suppress mitogen-induced proliferation of 
human lymphocytes and peripheral blood mononuclear cells while stimulating lymphocyte 
proliferation in the absence of mitogens (Kayser & Meisel, 1996). Other fragments (fragment 
18–20 of κ-casein, fragment 90–96 of αS1-casein) can either stimulate or inhibit lymphocyte 
proliferation depending upon the concentration used (Migliore-Samour et al., 1989; Kayser & 
Meisel, 1996). Maruyama et al. (1987) and later Kayser & Meisel (1996) reported that, in cell 
culture model systems, β-casomorphin-7 and β-casokinin-10 were immunoenhancing at high 
concentrations and immunosuppressing at low concentrations. 
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It was demonstrated that glycomacropeptide, a κ-casein derivative, inhibits the proliferation of 
splenocytes of mice (Otani & Hata, 1995) and enhances IgA production (Yun et al., 1996). 
Peptides derived from the fermentation of milk with L. helveticus showed the ability to 
stimulate proliferation of lymphocytes and phagocytic activity of pulmonary macrophages 
(Laffineur et al., 1996). The observations in vitro were confirmed by in vivo studies in mice: the 
administration of L. helveticus hydrolysates, followed by infection with E. coli caused an 
increase of IgA-secreting B cells. Instead, this effect was not observed by administering the 
hydrolysis product of a genetically modified, protease-negative, strain of L. helveticus, 
indicating an effect closely related to the proteolytic activity of the microorganism (LeBlanc et 
al., 2002). 
Some casein-derived peptides (residues 54–59 of human β-casein and residues 194–199 of 
bovine αS1-casein) can stimulate phagocytosis of sheep red blood cells by murine peritoneal 
macrophages (Parker et al., 1984; Jollés et al., 1992), exert a protective effect against Klebsiella 
pneumoniae (Migliore-Samour et al., 1989) or modulate immunoglobulin production in mouse 
spleen cell cultures (fragment 1–28 of bovine β-casein, (Otani & Hata, 1995; Otani et al., 2001). 
CHs have also been shown to have an effect on cytokine expression (Phelan et al., 2009a). 
Phelan et al. (2009b) demonstrated that CHs generated a Th1 response by enhancing ConA-
induced interleukin-2 (IL-2) production while having no effect on IL-10. Kawahara & Otani 
(2004) analysed the effect of the commercially available caseinophosphopeptide preparation 
CPP-III, consisting mainly of the fragments αS2-CN (1–32) and β-CN (1–28) from bovine 
caseins, on the mRNA expression of cytokines in Caco-2 cells. CPP-III enhanced mRNA 
expression of IL-6 and tumour necrosis factor-α (TNF-α), while IL-1β was not affected. mRNA 
expression of IL-6 was stronger in the presence of both CPPs-III and peptidoglycan from 
Lactobacillus acidophilus and lipopolysaccharide (LPS) from Salmonella typhimurium. Kitts & 
Nakamura (2006) showed that only one of the three analysed CPPs (CPPs-III) stimulated IL-6-
induced immunostimulation in intestinal epithelial-like cells Int-407. In vitro results suggest 
that CHs mainly affect the production of Th1 cytokines and, hence, have a role in cellular 
immunity (Phelan et al., 2009a). 
 
However, the mechanisms by which these milk-derived peptides exert their immunomodulatory 
effects or influence cell proliferation are not currently fully understood (Phelan et al., 2009a). 
Several immunomodulatory peptides are multifunctional peptides. Some of them may modulate 
cell proliferation via ACE-inhibitory mechanism. ACE-inhibitory peptides are known for their 
hypotensive properties, because they inhibit the conversion of angiotensin I to angiotensin II, 
but have also been found to prevent cleavage of bradykinin, that is mediated by ACE (Jollés et 
al., 1992). Bradykinin acts as a mediator of the acute inflammatory process and is thus able to 
enhance lymphocyte migration, stimulate macrophages, and induce the secretion of cytokines 
from lymphocytes in culture. It should be noted that a common structural feature of several 
ACE-inhibitory peptides and some immunomodulatory peptides is the presence of arginine as 
the C-terminal residue (Nagpal et al., 2011). 
The other example of multifunctional peptides is the opioid peptide β-casomorphin, derived 
from human β-casein. It inhibits in vitro the proliferation of human lamina propria lymphocytes 
via opiate receptor (Elitsur & Kuk, 1991). On the other hand, opioid peptides stimulate the 
maturation and proliferation of T cells and natural killer cells (Rutherfurd-Markwick & 
Moughan, 2005). Indeed, the immune system and opioid peptides are related: it has already 
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been demonstrated that opioid receptors are expressed on T lymphocytes and human phagocytic 
leukocytes (Meisel, 1998; Carr et al., 1989). 
It has been suggested that arginine in the N- or C-terminal region of a peptide is an important 
structural entity recognised by specific membrane bound receptors. A common structural 
feature among some immunomodulatory peptides is the presence of arginine in the C-terminal 
(Meisel, 1998; Nagpal et al., 2011). 
Caseinophosphopeptides, other class of casein-derived peptides with immunomodulatory 
activity, CPP-III in particular, enhance the proliferative response induced by LPS, 
phytohaemagglutinin and concanavalin A (ConA) stimulation, and immunoglobulin production 
in mouse splenocyte cultures (Hata et al., 1998; Hata et al., 1999). This immunostimulating 
activity was attributed to the o-phospho-L-serine residue, suggesting that such a bioactivity is 
relatively stable to proteinase action in the intestinal tract (Otani et al., 2000). The research 
paper of Otani et al. (Otani et al., 2003) focusing on the effects of CPP-III on serum and 
intestinal Ig G and Ig A secretion in mice, proved that oral use of CPP-III is beneficial toward 
enhancement of the mucosal immunity. 
 
1.2 Aims of the Study 
 
22 
1.2 AIMS OF THE STUDY 
Bovine milk contains a number of potent immunoregulatory peptides that affect the immune 
system via cellular functions and there is great interest in the immunomodulatory properties of 
casein hydrolysates (CHs) (Eriksen et al., 2008; Phelan et al., 2009a, 2009b). Hydrolysis of 
bovine milk caseins by CEPs of LAB can yield a number of immunologically active 
biopeptides, as it was mentioned above in the literature review. However, until recently little 
was known about interactions of these peptides with intestinal mucosae at the immunological 
level (Korhonen & Pihlanto, 2006; Phelan et al., 2009b). 
Therefore, the aim of the present study was to determine in vitro the immunomodulatory 
activity at the enterocyte level of bovine CHs produced by digestion with CEPs of LAB. 
Most specifically the tasks were: 
1. Examine proteolysis of bovine caseinate by CEP-positive LAB. 
2. Develop the system based on the response of intestinal epithelial-like Caco-2 cells and 
determine immunomodulatory activity in vitro of CHs, as a source of potential 
biologically active peptides. 
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1.3 MATERIALS AND METHODS 
1.3.1 Bacterial strains and culture conditions 
Table 1.3.1 lists the bacterial strains used in this study. S. thermophilus strains were grown at 37 
°C in M17 medium (Sigma–Aldrich, Milan, Italy) supplemented with 20 g of lactose liter-1. L. 
lactis subsp. lactis was cultivated in M17 medium supplemented with 0.5 % of lactose and 0.5 
% of glucose at 30 °C. L. helveticus and L. acidophilus were grown in MRS broth (Sigma–
Aldrich) supplemented with 1 % of Tween 80 (Sigma–Aldrich) at 37 °C. 
Table 1.3.1. Bacterial strains included in the study. 
Species Strain Source 
Streptococcus thermophilus 3207a 
CNRZ 385b 
DSM 20617T 
Yogurt obtained in Georgia-Kutaisi 
Japanese yogurt (Yakult Company) 
Pasteurized milk 
Lactobacillus helveticus MIMLh5a 
Lh164a 
ATCC 15009T 
Grana Padano cheese natural whey starter 
Natural whey starter 
Emmental (Swiss) cheese 
Lactobacillus acidophilus La-5c 
LA03d 
ATCC 4356T 
Commercial probiotic strain 
Commercial probiotic strain 
Human 
Lactococcus lactis subsp. lactis GR1a 
GR5a 
Sour cream obtained in Lithuania 
Sour cream obtained in Lithuania 
a
 DiSTAM Industrial Microbiology Section Culture Collection, University of Milan (Milan, 
Italy). 
b
 LAB collection of the Institut National de la Recherche Agronomique (Jouy-en-Josas, France). 
c
 Chr. Hansen A/S Culture Collection (Horsholm, Denmark). 
d
 Sacco Culture Collection (Cadorago, Italy). 
T
 Type strains from German Collection of Microorganisms and Cell Cultures (DSMZ, 
Braunschweig, Germany) and American Type Culture Collection (Manassas, VA, USA). 
 
1.3.2 Determination of CEP (prt) gene fragments 
Determination of CEP gene (prtS for S. thermophilus, prtH and prtH2 for L. helveticus, prtR for 
L. acidophilus and prtP for L. lactis subsp. lactis) fragments was performed by PCR using 
specific primers designed for the internal part of the protease genes (Table 1.3.2) on the DNA 
extracted from the isolates according the standard procedures (Sambrook et al., 2001). 
Table 1.3.2. Primers used in this study. 
Primer Sequence (5’ to 3’) Size of PCR product (bp) Reference 
PrtSf TGTTCCTGACGCAATCGTTCA 680 This study 
PrtSr CGTGCATACCGTGTGAACGT   
PrtH2-for-3 GTTGGTGCCGCAACTAAATC 430 Genay et al., 2009 
PrtH2-rev-2 TAGCATTTTGGTCAAAGACA   
PrtH-for-1 GGTACTTCAATGGCTTCTCC 470 Genay et al., 2009 
PrtH-rev-1 GATGCGCCATCAATCTTCTT   
PrtRf GTTGGTGCAGCAACTAAAGC 427 This study 
PrtRr TAGCTTTCTTGTCAAAGACA   
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Primer Sequence (5’ to 3’) Size of PCR product (bp) Reference 
P15C AACCAAATCTGATGTTG 560 Nikolic et al., 2009 
P06C TTTCAGCGGAAGCAACT   
 
The PCR conditions were as follows: predenaturation at 95 °C for 4 min, 30 cycles at 95 °C for 
30 s, 61 °C (for prtS), 58 °C (for prtH2, prtH and prtR), 55 °C (for prtP) for 30 s, 72 °C for 1 
min, and a single final extension at 72 °C for 7 min. All amplification reactions were performed 
in a MyCycler thermal cycler (BioRad Italia, Milan, Italy). 
1.3.3 Preparation of CHs 
Sodium caseinate was prepared from unprocessed bovine bulk milk. This milk was firstly 
skimmed and subjected to sodium caseinate preparation according to Hammarsten (1882–
1883). Bacterial strains were subjected to evaluation of sodium caseinate hydrolysis by CEPs as 
described by Arioli et al. (2007) and Hebert et al. (2008) with slight modifications. Briefly, 
overnight culture was harvested by centrifugation, washed twice with and resuspended in 0.85 
% (w/v) NaCl solution. Cell suspensions were incubated for 30 min at bacterial growth 
temperature before casein degradation was carried out (in order to consume residual amino 
acids and peptides), washed again with 0.85 % (w/v) NaCl solution and resuspended to a final 
OD600 of approximately 10 (which corresponded to approximately 1010 cells mL-1) in 0.1 M 
TRIS–HCl buffer (pH 8.0). Cell suspension was mixed with 10 mg mL-1 of sodium caseinate 
dissolved in 0.1 M TRIS–HCl (pH 8.0) at a ratio 9:1 (v/v). The resulting mixtures were 
incubated at bacterial growth temperature with slight agitation (140 rpm). After 5 h samples 
were centrifuged (8500 × g 4 °C for 10 min), filtered through a 0.2-µm-pore-size sterile 
cellulose acetate membrane filter (Albet-Hahnemuehle, Barcelona, Spain) and subjected to 
ultrafiltration and reverse phase high-performance liquid chromatography (RP–HPLC) analysis. 
Peptides of less than 3 kDa were separated from whole CHs using ultrafiltration through 
Ultracel regenerated cellulose ultrafiltration membrane NMWL 3000 (Millipore, Vimodrone, 
Italy). 
1.3.4 Evaluation of sodium caseinate hydrolysis by RP–HPLC 
Before analysis, samples were diluted 1:4 with a solution containing 8 M urea and 0.1 % 
trifluoroacetic acid (TFA) in MilliQ-treated water (Millipore). After resting at room temperature 
for at least 15 min, samples were analyzed by RP–HPLC on Waters Alliance 2695 instrument 
(Waters, Vimodrone, Italy). Proteins and peptides were separated at 40 °C on a PLRP-S column 
(2.1 mm i.d., 5 µm, 300 Å, Polymer Laboratories Ltd, Church Stretton, UK). The eluents used 
for the separation were: solvent A, 0.1 % TFA in MilliQ-treated water, and solvent B, 0.1 % 
TFA in acetonitrile. The linear elution gradient expressed as the solvent B proportion was as 
follows: 0 min, 30 %; 0 to 5 min, 30 %; 5 to 40 min, 30 to 50 %; 40 to 41 min, 50 to 95 %; 41 
to 45 min, 95 %; 45 to 46 min, 95 to 30 % (run-to-run time, 50 min). Proteins and peptides were 
eluted at a flow rate of 0.2 mL min-1 and monitored at 210 nm. 
1.3.5 Cultivation of Caco-2 cells 
Caco-2 cells were routinely grown as previously explained (Guglielmetti et al., 2008). In brief, 
Caco-2 were cultivated in 9-cm diameter Petri plates in Eagle’s minimum essential medium 
supplemented with 10 % (v/v) heat-inactivated (30 min at 56 °C) foetal calf serum, 100 U mL-1 
penicillin, 100 mg mL-1 streptomycin, 0.1 mM nonessential amino acids, and 2 mM L-
glutamine (EMEM) and incubated at 37 °C in a water-jacketed incubator in an atmosphere of 
95 % air and 5 % carbon dioxide. The culture medium was changed twice weekly. 
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1.3.6 Construction of stable NF-κB reporting Caco-2 cells 
Stable transfectants of Caco-2 cell line were obtained after transfection with the plasmid 
pNiFty2-Luc (Figure 1.3.1; InvivoGen, Labogen, Rho, Italy). 
 
Figure 1.3.1. Genetic map of a plasmid pNiFty2-Luc. 
This plasmid contains promoter combining five NF-κB-
binding sites and the firefly luciferase reporter gene luc. 
The presence of NF-κB activating molecules in the cell 
activates this transcription factor, which binds to the 
promoter, resulting in the expression of the luciferase 
gene. 
 
Transfection was performed and stable recombinant clones were selected as described in 
Guglielmetti et al. (2010a). Briefly, Caco-2 were transfected by means of the StoS transfection 
kit (GeneSpin, Milan, Italy), in accordance with the manufacturer’s protocol. Afterward, cells 
were resuspended in fresh EMEM, seeded in 24-well plates, and incubated for 48 h, in order to 
obtain the expression of the antibiotic resistance. Finally, stable recombinant clones were 
selected by adding into the culture medium 50 µg ml-1 of zeocin (InvivoGen). 
1.3.7 Evaluation of immunomodulatory activity of CHs 
Recombinant Caco-2 cells were cultured in 24-well plates in presence of 50 µg mL-1 zeocin. 
Cell monolayers (approximately 3 × 105 cells well-1) were carefully washed with 0.1 M TRIS-
HCl buffer (pH 8.0), and 1.35 mL of fresh EMEM medium, containing 25 mM of HEPES (pH 
7.4), was added. Subsequently 0.15 mL of CHs (which correspond to 150 µg of hydrolysed 
sodium caseinate) were added into each well. After incubation at 37 °C for 4 h, 24-well plates 
were put on ice for 15 min; recombinant Caco-2 cells were detached mechanically from the 
bottom of a well, samples were transferred into an eppendorf tube and subjected to sonication at 
maximum power for 5 s using a Bandelin SONOPLUS Ultrasonic Homogenizer (Bandelin 
electronic GmbH & Co., Berlin, Germany). Insoluble particles were removed by centrifugation 
and the supernatants were transferred into a new tube. One hundred µL of supernatants were 
aliquoted in duplicate into the wells of a 96-well white microtiter plate (PerkinElmer, Monza, 
Italy) by means of epMotion Automated Pipetting System (Eppendorf, Milan, Italy). Then 12.5 
µL of a 10 mM ATP solution (i.e. up to the final concentration of 1 mM) and 12.5 µL of 0.1 
mM D-luciferin were added and the emitted bioluminescence was immediately measured every 
120 s with a VICTOR3 1420 Multilabel Counter (PerkinElmer). The maximum of light-
production curve was considered for comparison of results. In a different set of experiments, 
recombinant Caco-2 cells were simultaneously stimulated with IL-1β (2 ng mL-1). All CHs 
were analysed in duplicate in at least three independent experiments. 
1.3.8 Statistical analysis 
The significance of the results in the experiments for the evaluation of immunomodulatory 
activity of CHs was analysed by unpaired heteroscedastic Student’s t test with two-tailed 
distribution. Differences of P < 0.05 were considered to be significant. 
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1.4 RESULTS AND DISCUSSION 
1.4.1 Proteolytic activities of lactic acid bacterial strains 
The CEPs of LAB substantiate food fermentation process and ensure bacterial growth 
(Christensen et al., 1999; Siezen, 1999). Moreover, they have the ability to liberate from food 
proteins a large variety of peptides with potential biological activities (Hebert et al., 2008; 
Hernandez-Ledesma et al., 2004). Therefore, eleven different LAB strains were selected for 
analysis: 3 belonging to the species S. thermophilus (3207, CNRZ 385, DSM 20617), 3 to the 
species L. helveticus (MIMLh5, Lh164, ATCC 15009), 3 to the species L. acidophilus (La-5, 
LA03, ATCC 4356), and 2 L. lactis subsp. lactis strains (GR1, GR5). 
S. thermophilus CNRZ 385 possesses a proteolytic activity and its CEP (called PrtS) has been 
extensively characterised (Shahbal et al., 1991; Shahbal et al., 1993; Fernandez-Espla et al., 
2000; Courtin et al., 2002). Also, it was demonstrated that L. helveticus ATCC 15009 has cell 
surface proteinase activity, as measured by the hydrolysis of fragment f1-23 of αS1-casein 
(Pederson et al., 1999; Jensen et al., 2009). Moreover, caseinolytic properties of dairy L. 
helveticus and L. lactis strains are well documented (Jensen et al., 2009; Nikolic et al., 2009). 
Using specific primers designed for the internal part of the protease genes (Table 1.3.2), in PCR 
reactions on the DNA extracted from the isolates we obtained the expected length PCR 
fragments for bacterial CEP genes in six other analysed LAB strains: prtS in S. thermophilus 
3207, prtH2 in L. helveticus MIMLh5 and Lh164, prtR in L. acidophilus LA03 and ATCC 
4356, and prtP in L. lactis subsp. lactis GR5, and confirmed the presence of prtS in S. 
thermophilus CNRZ 385 and prtH2 in L. helveticus ATCC 15009. L. acidophilus La-5 and L. 
lactis subsp. lactis GR1 were protease-negative. S. thermophilus DSM 20617 was selected as a 
protease-negative control (Arioli et al., 2007). 
All eight CEP-positive strains were subjected to sodium caseinate hydrolysis with the scope to 
obtain hydrolysates with immunomodulatory activities. Hydrolysis profiles, paying the largest 
attention for the hydrolysis of αS1 and β caseins as the major potential source of bioactive 
peptides with immunomodulatory activities (for a recent review see Phelan et al., 2009a), were 
analysed by RP–HPLC (Figure 1.4.1). 
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In accordance to the absence of CEP activity in S. thermophilus DSM 20617, chromatographic 
profile showed that sodium caseinate was not hydrolysed after treatment with this strain (Figure 
1.4.1). Caseinate profiles in the presence and in the absence of S. thermophilus DSM 20617 
cells were demonstrated to be identical (data not shown). On the contrary, in the case of sodium 
caseinate hydrolysis with S. thermophilus strain CNRZ 385, after five hours of proteolysis, we 
noticed the decrease of β-casein fraction and a slight digestion of αS1-casein. The change in αS1-
casein fraction profile was demonstrated also with S. thermophilus strain 3207, whereas 
hydrolysis of β-casein was not appreciable. 
In the case of L. acidophilus strain ATCC 4356, there is the shift in the location of the αS1-
casein peak from the “undigested casein” control that likely indicates the cleavage of a peptide 
from this casein fraction. This strain strongly digested β-casein, and the proteolytic activity 
against this protein was comparable to that observed for S. thermophilus strain CNRZ 385. 
Instead, LA03 had no effect on β-casein, but digested αS1 form. Similarly, but at a different 
degree, the three tested L. helveticus strains (MIMLh5, Lh164 and ATCC 15009), demonstrated 
to proteolyse only αS1 form. Finally, L. lactis subsp. lactis GR5 degraded β-casein and to a 
lesser extent αS1 form, similarly to that revealed for S. thermophilus CNRZ 385 strain. 
As all analysed CEP-positive strains demonstrated proteolytic activity against sodium caseinate 
and showed the diverse hydrolytic ability against different casein fractions, this could determine 
diverse immunomodulatory activities of derived CHs. 
1.4.2 Immunomodulatory activities of CHs 
CHs, produced after digestion with proteinases of the eight CEP-positive bacterial strains, were 
tested for a potential immunomodulatory activity. In this regard, it has been evaluated the 
capability of hydrolysates to modulate the activation of transcription factor NF-κB in Caco-2 
cells. These cells from human colorectal adenocarcinoma (Fogh et al., 1977), after about two 
weeks of differentiation, share the morphological and functional properties of mature intestinal 
cells, such as enterocytes or mucus cells, and therefore are valuable in vitro tools for studies 
related to intestinal cell function and immune response. NF-κB reporter system was chosen as 
this transcription factor regulates many physiological processes, including the innate- and 
adaptive-immune responses, cell death and inflammation (Gilmore, 2006; Perkins, 2007). NF-
κB is a critical transcription factor that functions to enhance the transcription of many cytokines 
(including tumour necrosis factor (TNF)-α, IL-1, IL-6, and IL-8, which are thought to be 
important in the generation of acute inflammatory responses), growth factors, adhesion 
molecules, immunoreceptors, and acute-phase proteins. Activated NF-κB initiates both 
extracellular and intracellular regulatory events that result in autoregulation of the inflammatory 
cascade through positive and negative feedback loops (Blackwell & Christman, 1997). 
On these bases, eight CHs, produced after digestion with LAB CEPs, were tested for their 
ability to modulate NF-κB activation in recombinant Caco-2 cells. Two of them, deriving from 
digestion with L. helveticus MIMLh5 and L. acidophilus ATCC 4356 CEPs, were found to 
significantly decrease the basal NF-κB activity (Figure 1.4.2), therefore they demonstrated 
immunomodulatory activity. These hydrolysates were selected for subsequent analysis. 
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Figure 1.4.2. Effects of whole CHs, produced 
after digestion with LAB strains on 
recombinant Caco-2 cells. Luciferase activity 
is expressed as percentual change in relative 
luminescence units, assuming the control as 
100 %. Control, Caco-2 incubated with 
undigested sodium caseinate. The values are 
the means (± standard deviation) of at least 
three independent experiments conducted in 
duplicate. Different asterisks (*) indicate 
statistically significant differences compared 
to control. 
 
Several works in literature indicate the immunomodulatory activity induced by bovine milk 
fermentation products with strains of L. helveticus. The group of Matar published a series of 
papers, demonstrating immunomodulating effects of milks fermented by L. helveticus R389 and 
evidencing peptidic fractions, responsible for this activity (Matar et al., 1996; Matar et al., 
2001; LeBlanc et al., 2002; LeBlanc et al., 2004). It was clearly demonstrated that the 
mentioned strain itself did not induce mucosal and tumoural immunity (Matar et al., 2001). 
Fujiwara and colleagues (Fujiwara et al., 1990) suggested that L. helveticus fermented milk 
products induced mitogenic activity. L. helveticus 5089-fermented milk has demonstrated 
immunomodulating effects on lymphocyte proliferation in vitro (Laffineur et al., 1996) and the 
ability to stimulate the phagocytic activity of pulmonary macrophages. However, both papers 
attribute immunomodulatory activity to casein-derived peptides and do not take in consideration 
the potential activity due to the presence of L. helveticus cell components in the fermented 
milks. 
Since we have recently demonstrated that L. helveticus MIMLh5 strain by itself modulates the 
immune response (Guglielmetti et al., 2010b), it is paramount to avoid the presence of bacterial 
cell components in CHs. With this aim CH were ultrafiltered using a 3 kDa membrane and the 
permeate was tested for ability to modulate NF-κB activation in recombinant Caco-2 cells. In 
fact, the MIMLh5 hydrolysate after 3 kDa-ultrafiltration did not modulate NF-κB activation in 
recombinant Caco-2 cells, i.e. it lost immunomodulatory activity (Figure 1.4.3). 
 
Figure 1.4.3. Effects of fractionated 
(ultrafiltration 3 kDa) CHs, produced after 
digestion with LAB CEPs, on recombinant 
Caco-2 cells. Control, Caco-2 incubated with 
undigested and 3 kDa-ultrafiltered sodium 
caseinate. The values are the means (± 
standard deviation) of at least three 
independent experiments conducted in 
duplicate. Asterisks (*) indicate statistically 
significant differences compared to control. 
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This result let us presume the possible presence in such “hydrolysates” of bacterial cell 
components that detach easily from cell surfaces during hydrolysate preparation. We proved the 
presumption that the observed difference was due to cell components, by incubating the cells 
under the same conditions, but in the absence of casein. Also in this case permeate of 3 kDa-
ultrafiltration did not cause the significant decrease in NF-κB activation (Figure 1.4.4). 
 
Figure 1.4.4. Effects of fractionated (ultrafiltration 3 kDa) 
CHs, produced after 0 and 5 h digestion with L. helveticus 
MIMLh5 CEP, on recombinant Caco-2 cells in the 
presence (+cas) and in the absence (-cas) of sodium 
caseinate. 0h+cas, CH, prepared after 0 h digestion with 
bacterial proteinase; 0h-cas, hydrolysis reaction buffer, 
incubated 0 h with bacterial cells; 5h+cas, CH, prepared 
after 5 h of sodium caseinate contact with bacterial cells; 
5h-cas, hydrolysis reaction buffer, incubated 5 h with 
bacterial cells. Control, Caco-2 incubated with undigested 
and 3 kDa-ultrafiltered sodium caseinate. The values are 
the means (± standard deviation) of three independent 
experiments conducted in duplicate. 
 
Secondly, we incubated “CH”, produced after 0 h digestion with L. helveticus MIMLh5 
proteinase, i.e. the non-hydrolysed casein after the short contact with bacterium. In this instance 
the non-fractionated sample determined a significant decrease of the basal NF-κB activity 
(Figure 1.4.5), in contrast to the observation that non-fractionated caseinate sample by itself 
does not modulate the NF-κB activation in Caco-2 reporter cell line. 
 
Figure 1.4.5. Effects of non-fractionated CHs, produced 
after digestion (0 h and 5 h) with L. helveticus MIMLh5 
CEP, on recombinant Caco-2 cells in the presence (+cas) 
and in the absence (-cas) of sodium caseinate. 0h+cas, 
CH, prepared after 0 h digestion with bacterial proteinase; 
0h-cas, hydrolysis reaction buffer, incubated 0 h with 
bacterial cells; 5h+cas, CH, prepared after 5 h of sodium 
caseinate contact with bacterial cells; 5h-cas, hydrolysis 
reaction buffer, incubated 5 h with bacterial cells. Control, 
Caco-2 incubated with undigested sodium caseinate. The 
values are the means (± standard deviation) of three 
independent experiments conducted in duplicate. Asterisks 
(*) indicate statistically significant differences compared 
to control. 
 
These two results suggest the origin of immunomodulatory activity deriving from the tested 
bacterium and let us argue the absence of NF-κB activating peptides in CHs, produced by 
proteolytic activity of MIMLh5. In general, these results underline the importance to consider 
bacterial components of the > 3kDa size class when evaluating the immunomodulatory activity 
of non-fractionated CHs. 
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Subsequently, we continued our investigation with the other immunologically active CH, 
produced after digestion with CEP of L. acidophilus ATCC 4356. 
Scarce data about immunomodulatory activity of L. acidophilus strains are present in the 
scientific literature. In one case the origin of this activity has been clearly demonstrated by 
Konstantinov et al. (2008) who showed that the immunomodulatory activity of L. acidophilus is 
determined by its S-layer. To our knowledge, the data about L. acidophilus ATCC 4356 
immunomodulatory activity are absent. Analogously, we tested the immunomodulatory activity 
of the 3 kDa-ultrafiltered CH, produced after digestion with the CEP of L. acidophilus ATCC 
4356. Contrary to CH produced after digestion with CEP of L. helveticus MIMLh5, the 3 kDa-
ultrafiltered CH produced by L. acidophilus ATCC 4356 retains immunomodulatory activity 
demonstrating NF-κB activation in recombinant Caco-2 cell monolayers (Figure 1.4.3 and 
Figure 1.4.6A). 
 
Figure 1.4.6. Effects of fractionated (ultrafiltration 3 kDa) CHs, produced after digestion (0 h 
and 5 h) with L. acidophilus ATCC 4356 (A) and L. lactis subsp. lactis GR5 (B) CEPs, on 
recombinant Caco-2 cells in the presence (+cas) and in the absence (-cas) of sodium caseinate. 
0h+cas, CH, prepared after 0 h digestion with bacterial CEP; 0h-cas, hydrolysis reaction 
buffer, incubated 0 h with bacterial cells; 5h+cas, CH, prepared after 5 h of sodium caseinate 
contact with bacterial cells; 5h-cas, hydrolysis reaction buffer, incubated 5 h with bacterial 
cells. Control, Caco-2 incubated with undigested and 3 kDa-ultrafiltered sodium caseinate. The 
values are the means (± standard deviation) of at least three independent experiments 
conducted in duplicate. An asterisk (*) indicates statistically significant differences compared 
to control. 
 
It can be supposed that non-fractionated CHs contain peptides that enhance or suppress NF-κB 
activation and, therefore, synergistic action of these peptides does not give immunomodulatory 
response. For this reason, other six CHs (that intact did not modulate NF-κB activation in 
recombinant Caco-2 cells), produced after digestion with CEP of L. helveticus Lh164 and 
ATCC 15009, L. acidophilus LA03, L. lactis subsp. lactis GR5, S. thermophilus 3207 and 
CNRZ 385, were ultrafiltered (3 kDa) and tested for immunomodulation. Interestingly, 3 kDa-
fraction of CH produced by L. lactis subsp. lactis GR5 strain significantly decreased the basal 
NF-κB activity in Caco-2 reporter cell monolayers (Figure 1.4.3). To confirm or reject the 
possible presence of bacterial cell components in this fractionated CH, the GR5 strain was also 
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incubated for 0 and 5 h in the presence and in the absence of sodium caseinate. The derived 
hydrolysates were ultrafiltered through 3 kDa-membrane and tested for immunomodulatory 
activity. The abolishment of NF-κB activation, obtained with hydrolysates, produced after 5 h 
of digestion with CEP of L. lactis subsp. lactis GR5, was confirmed (Figure 1.4.6B). 
Further, the anti-inflammatory activity of all 3 kDa-fractionated CHs was tested. For this 
reason, recombinant Caco-2 cells were co-stimulated with 3 kDa-fractionated CHs and IL-1β, a 
prototypical pro-inflammatory cytokine that plays a central role in the inflammation 
amplification cascade. The addition of 2 ng mL-1 of IL-1β to Caco-2 culture medium caused 
nearly a twofold increase of NF-κB activity after 4 h incubation. In this experiment we also 
used a synthetic anti-inflammatory tripeptide KPV (Primm, Milan, Italy) (Dalmasso et al., 
2008) as a positive control. After stimulation by IL-1β, tripeptide KPV significantly reduced the 
NF-κB activation, while the control hydrolysate (intact sodium caseinate, ultrafiltered through 3 
kDa membrane) did not have any significant effect (Figure 1.4.7). 
 
 
Figure 1.4.7. Effects of fractionated 
(ultrafiltration 3 kDa) CHs, produced 
after digestion with LAB CEPs, on 
recombinant Caco-2 cells in the presence 
of co-stimulation with IL-1β. KPV, a 
synthetic tripeptide KPV, 10 nM. The 
values are the means (± standard 
deviation) of at least three independent 
experiments conducted in duplicate. An 
asterisk (*) indicates statistically 
significant differences compared to 
control. 
 
 
Finally, we observed that the 3 kDa-fraction of CH produced by L. lactis subsp. lactis GR5 
strain significantly decreased the basal NF-κB activity in the presence of IL-1β thus showing 
anti-inflammatory activity in recombinant Caco-2 cell layers (Figure 1.4.7 and Figure 1.4.8). 
 
 
Figure 1.4.8. Effects of fractionated (ultrafiltration 3 kDa) 
CHs, produced after digestion with L. lactis subsp. lactis 
GR5 CEP on recombinant Caco-2 cells in the presence of 
co-stimulation with IL-1β in the presence (+cas) and in the 
absence (-cas) of sodium caseinate. The values are the 
means (± standard deviation) of at least three independent 
experiments conducted in duplicate. An asterisk (*) 
indicates statistically significant differences compared to 
control. 
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1.5 CONCLUSIONS 
According to the tasks described in the chapter 1.2, the following conclusions were drawn: 
1. In this study different proteolytic specificity of CEPs on casein fractions was observed 
among the tested LAB strains. 
2. The developed stable NF-κB reporting Caco-2 cell line demonstrated to be an accurate 
tool for evaluating the immunomodulatory activity of CHs. 
3. This work established that 3 kDa-ultrafiltered CHs, produced after digestion with 
CEPs of L. acidophilus ATCC 4356 and L. lactis subsp. lactis GR5, significantly 
decreased the basal NF-κB activity in recombinant Caco-2 cell layers, thus 
demonstrating immunomodulatory activity. Both the strains digested β-casein mostly. 
In the case of L. helveticus MIMLh5, the investigation proved that the immunomodulatory 
activity of obtained CH was not due to casein-derived peptides. This activity was strong and 
comparable to the one exerted by bacteria themselves, as demonstrated by Guglielmetti et al. 
(2010b). Indeed, the surface layer (S-layer) protein of L. helveticus MIMLh5 was identified as 
responsible for the immunomodulation (Taverniti et al., manuscript in preparation). For this 
reason, the second part of the research was focussed on the development of S-layer protein-
specific binders, a new powerful tool for the study of this immunologically active protein and 
for its identification in milk-derived products containing L. helveticus as a starter or non starter 
LAB. 
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2.1 STATE OF THE ART 
Lactobacilli are rod-shaped Gram-positive non-spore-forming bacteria characterised by the 
formation of lactic acid as a sole or main end product of their sugar fermentation. Particularly, 
the genus Lactobacillus is the largest included in LAB with over hundred species recognised at 
present. It is very heterogeneous containing species with substantial differences in their 
phenotypic, biochemical, physiological and genotypic characteristics. 
L. helveticus is a thermophilic homofermentative microorganism. Several strains are claimed to 
be health-benefiting to their host (Tuohy et al., 2003; Johnson-Henry et al., 2007; Guglielmetti 
et al., 2010) and are therefore currently used as probiotic supplements in several commercial 
products [e.g. “Evolus” (Valio, Finland), “Ferzym plus” (Specchiasol, Italy), “A’Biotica” 
(Institut Rosell, Canada), “All-Flora” (New Chapter, USA)]. The species demonstrates high 
proteolytic activity, which is favourable in some industrial processes, for instance highly 
contributing to cheese ripening. In fact, L. helveticus has an important role in the production of 
American Swiss, Emmental, Cheddar, Parmesan, Pecorino Romano, Provolone, Grana Padano 
cheeses (Lortal, 2004). Due to the long history of use in food fermentations and in the food 
industry as well as lack of pathogenicity, L. helveticus is a generally recognised as safe (GRAS) 
organism, which has received the Qualified Presumption of Safety (QPS) status by the 
European Food Safety Authority (EFSA, 2004). 
2.1.1 S-layer proteins of Lactobacillus spp. 
Surface (S-) layers are crystalline arrays of proteinaceous subunits present as the outermost 
component of cell wall in several species of the genus Lactobacillus, as well as in many other 
bacteria and Archaea (Sára & Sleytr, 2000). S-layer is composed from one single protein or 
glycoprotein, forming crystalline structure of 5–15 nm with identical pores, which have 
diameter of 2–8 nm (Sleytr, 1997). The pores comprise up to 70 % of the lattice surface area 
(Sleytr & Beveridge, 1999). S-layer proteins have the ability to self-assemble into 
monomolecular crystalline arrays. The S-layer lattice can exhibit oblique (p1, p2), square (p4) 
or hexagonal (p3, p6) symmetry. From the Lactobacillus S-layer proteins, only oblique and 
hexagonal lattice types have been characterised (Figure 2.1.1), but in most cases, only a 
periodic structure, without further characterisation, has been observed using electron 
microscopy analysis. Problems related to electron microscopy of Lactobacillus S-layers have 
been reported, and these problems may be one of the reasons why the lattice type and lattice 
constants have not been determined for most of the S-layer proteins of these bacteria (Åvall-
Jääskeläinen & Palva, 2005). 
A B 
Figure 2.1.1. Scanning 
electron micrograph of 
a freeze-etched 
preparation of a 
bacterial cell with an S-
layer with oblique (p2; 
A) and hexagonal (p6; 
B) lattice symmetry. 
Scale bar = 100 nm. 
Adapted from Sleytr & 
Beveridge (1999). 
2.1 State of the Art 
 
43 
S-layer proteins are normally the most abundant bacterial proteins, constituting even up to 15 % 
of total bacterial protein content (Åvall-Jääskeläinen & Palva, 2005). In the case of L. 
helveticus, it forms around 45 % of cell wall dry weight (Messner et al., 1997). 
Most of the S-layer proteins of the genus Lactobacillus appear to be non-glycosylated, and up to 
date all known L. helveticus S-layer proteins are known not to have this modification. The S-
layer monomers are non-covalently linked to each other as well as to the supporting cell wall. 
The overall lack of identity between the S-layer proteins of different species is a common 
characteristic of all bacterial S-layer proteins. Lactobacilli make no exception in this respect 
(Åvall-Jääskeläinen & Palva, 2005; Gatti et al., 2005). The highest similarity can be found in 
the C-terminal region. The N-terminal regions are more variable except the signal peptides (N-
terminal secretion signals) that share a high level of sequence similarity. 
Typical characteristics of Lactobacillus spp. S-layer proteins, distinguishing them from other S-
layer proteins, is small size, ranging from 25 to 71 kDa and thus being among the smallest 
known for the S-layer proteins, which can be up to 200 kDa (Åvall-Jääskeläinen & Palva, 
2005). S-layer proteins of lactobacilli have high content of positively charged residues, which 
makes them highly basic proteins: predicted isoelectric point (pI) values range from 9.35 to 10.4 
(Mobili et al., 2010). A characteristic feature of Lactobacillus spp. S-layer proteins is a high 
percentage (23–33 %) of amino acid residues with hydroxyl groups and a high content of 
hydrophobic amino acid residues, ranging from 31.9 % to 38.7 %, which is a typical feature for 
all S-layer proteins (Åvall-Jääskeläinen & Palva, 2005). 
The functional roles of Lactobacillus spp. S-layers are yet poorly characterised. It was 
demonstrated that it can be involved in mediating adhesion to different host surfaces, even if 
this is not the case for all the microorganisms that have this protein (Sára & Sleytr, 2000). It 
was demonstrated that S-layers of L. helveticus and L. acidophilus can participate in the 
interaction between bacterium and its host (Johnson-Henry et al., 2007; Konstantinov et al., 
2008; Beganović et al., 2011). Konstantinov and colleagues demonstrated the ability of the S-
layer protein of L. acidophilus NCFM to interact with human’s immune system, determining 
the modulation of dendritic cell response and the activation of T-helpers (Konstantinov et al., 
2008). It is worth noting that the S-layer of L. acidophilus NCFM is highly similar to that of L. 
helveticus. Beganović and collaborators found that the S-layer protein is involved in the 
autoaggregation of L. helveticus M92 cells and coaggregation of L. helveticus M92 with 
Salmonella enterica serovar Typhimurium FP1. Moreover, it enhances the immune protection 
by reducing the infection by S. enterica serovar Typhimurium FP1 in vivo (Beganović et al., 
2011). 
A general functional principle for all S-layers has not been determined and probably does not 
exist, due to the widespread occurrence of S-layer-possessing organisms and their differences in 
the overall cell surface structure. Due to their highly periodic and regularly arranged porous 
ultrastructure, S-layers possess great potential for various applications in biotechnology, 
nanotechnology, nanobiotechnology and biomedical applications (Sára & Sleytr, 2000; Sleytr et 
al., 2003; Åvall-Jääskeläinen & Palva, 2005; Pum et al., 2006; Schuster & Sleytr, 2009; 
Hollmann et al., 2010). 
2.1.2 Binders from phage antibody libraries 
There are two methods for generating of monoclonal antibodies. The first one comprehends 
mice immunisation followed by hybridoma technology. In this technology hybrid cell lines 
(called hybridomas) are formed by fusing a specific antibody-producing B cell with a myeloma 
(B cell cancer) cell that is selected for its ability to grow in tissue culture and for an absence of 
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antibody chain synthesis. The production of monoclonal antibodies was invented by Cesar 
Milstein and Georges J. F. Köhler in 1975. 
Over the past twenty five years, advances in molecular biology have allowed to use the 
bacterium Escherichia coli for production of recombinant binders (antibodies) employing the 
phage display technology. 
2.1.2.1 Phage display 
Definition. In phage display, a foreign peptide, protein or antibody fragment is expressed on the 
phage surface due to the new genetic material inserted into a phage genome, fused to a capsid 
protein-encoding gene. The first report of phages displaying foreign peptides on their surface 
was published in 1985 (Smith, 1985). 
Antibody formats. Usually only a fragment of the entire antibody is being expressed due to the 
size limitations for protein production in bacteria. However, this antigen-recognising part is 
enough for the complete functionality. Antibody fragments most often used in phage display are 
either of single-chain variable fragment (scFv) or Fab format (Figure 2.1.2). 
 
 
 
Figure 2.1.2. Schematic antibody structure and derived fragments. (A) Schematic structure of 
an immunoglobulin molecule, (B) Fab and (C) scFv antibody fragments. Immunoglobulin 
consists of two identical heavy and light chains composed of variable and constant domains. 
VH, variable region of heavy chain; VL, variable region of light chain; CH, constant region of 
heavy chain; CL, constant region of light chain. The antigen-binding site is located at the tip of 
the variable domains. (D) The schematic structure of a scFv fragment gene. A scFv fragment 
consists of a VL and VH domains, which are linked through a flexible glycine-serine linker. 
Hypervariable complementarity-determining regions (CDR) that form the antigen-binding 
surface in a folded protein are indicated: CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, 
CDR-H3. Adapted from Smith et al. (2004) and Brockmann (2010). 
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Display systems. Four kinds of display system have been developed so far, namely, phage 
lambda, T4 phage, T7 phage and filamentous phage, the filamentous M13 phage being the most 
widely distributed (Kehoe & Kay, 2005). In M13 filamentous phage display, several coat 
proteins have been used as targets for the fusion of foreign peptides. The first and most 
commonly used is the p3 coat protein (Smith, 1985), which is present at three to five copies in 
M13 (Figure 2.1.3). The major coat protein p8 (2670 copies per phage particle) is also used 
(Benhar, 2001). 
Phage display formats. Phage display systems can be 
grouped into two classes on the basis of the vector 
system used for the production of phages (Paschke, 
2006). (1) True phage vectors are directly derived from 
the genome of filamentous phage (M13, f1, or fd) and 
encode all the proteins needed for the replication and 
assembly of the filamentous phage. Early phage display 
formats involved the peptide, protein or antibody 
fragment-encoding gene fusion to the phage capsid 
protein-encoding gene. In this case, they were displayed 
in a multivalent format, since all copies of the coat 
protein are translated as fusion proteins (Carmen & 
Jermutus, 2002). However, it was not possible to display 
larger polypeptides or proteins without affecting the 
function of capsid protein or decreasing of phage 
infectivity. These problems are overcome by the use of 
phagemids. The second group of phage display systems 
utilises (2) phagemid vectors, which produce the fusion 
coat protein. Phagemids are plasmids (approximately 4.6 
kilobases) which encode a signal sequence, the phage 
coat protein and an antibiotic resistance marker. The 
antibody fragment is cloned upstream (for N-fusions) or 
downstream (for C-fusions) of the capsid protein 
sequence and expression is controlled by the use of a promoter such as lacZ. The relatively 
small size of these vectors means that they have higher transformation efficiencies than phage 
vectors, hence facilitating the construction of large libraries of peptide or antibody fragments. 
The incorporation of an amber stop codon between the displayed protein and the phage coat 
protein permits fusion protein expression in suppressor strains of E. coli such as XL1-Blue. 
Non-suppressor strains, such as HB2151, will not incorporate a glutamine at the amber codon, 
thereby resulting in production of only the antibody moiety. A phagemid cannot produce 
infective phage particles alone. A helper phage (such as VCSM13; for monovalent display) or a 
hyperphage (a helper phage with a deletion in the p3 gene, but with wild type p3 phenotype, 
thus capable of infecting F+ E. coli cells with high efficiency (for polyvalent display, Broders et 
al., 2003) is required. The helper phage provides the genes which are essential for phage 
replication and assembly. Cells already containing the phagemid vector are superinfected with 
the helper phage. Glucose in the growth media represses the lacZ promoter, preventing 
expression of fusion, which would inhibit superinfection. Once the helper phage genome is 
incorporated into the cell, the glucose is removed and phage production starts. In addition, lacZ 
promoter is being induced with IPTG. 
Advantages of phage display technology. (1) Fast. One of the major advantages of phage 
display technology of antibody fragments compared with standard hybridoma technology is that 
the generation of specific fragment can be performed within a couple of weeks (Carmen & 
Figure 2.1.3. Schematic 
structure of filamentous M13 
phage and the principle of 
monovalent phage display. 
Adapted from Smith et al. 
(2005). 
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Jermutus, 2002). As this method is based on microbial systems, selection and screening are 
more amenable to automation than earlier hybridoma-based approaches. This provides the 
potential for high-throughput generation of binders (Babel et al., 2011). (2) The immediate 
availability of the antibody gene provides much additional value relative to antibodies obtained 
by immunising animals. By permitting control over selection and screening conditions, display 
technologies allow (3) the generation of antibodies against defined antigen conformations or 
epitopes. Because the gene encoding the antibody is cloned at the same time as the antibody is 
selected, simple subcloning steps after in vitro display permit (4) the creation of constructs with 
added functionalities: fusion to enzymes or biotin, multimerisation. In addition, (5) antibody 
specificities can be broadened or narrowed by appropriate selection and screening. Antibody 
generation by phage display overcomes immunological tolerance, allowing the selection of (6) 
affinity reagents that recognise highly conserved targets such as histones, haemoglobins and 
post-translational modifications. On the other hand, in vitro display technologies allow (7) the 
generation of antibodies, which recognise antigens that are neither immunogenic nor highly 
conserved (e.g. small molecules and chemical modifications). By in vitro methods it is possible 
to select (8) antibodies against pathogens and toxins, that are not obtainable by traditional 
immunisation techniques. Unlike antibodies generated by immunisation, the in vitro selected 
ones (especially those of human origin) have the potential to be used therapeutically as 
molecules with improved tolerance by the patients. 
The disadvantage of phage display selection of antibodies is that quite often antibodies with low 
affinities for the target are obtained. However, it turns to the major advantage of in vitro 
methods: once obtained it is possible to further improve the antibodies’ affinity, specificity, 
expression or stability. The improvement of antibody affinity even to femtomolar range became 
possible (the affinities of antibodies obtained by immunisation are limited to ~100 pM by the 
physiological mechanism of B-cell activation) (Bradbury et al., 2011). 
In their recent paper Andrew Bradbury and colleagues (Bradbury et al., 2011) raise a question: 
why antibodies selected by in vitro methods (even if being so powerful tools) are not widely 
perceived as valuable research reagents? Their answer is that difficult patent situation exists, 
which resulted in restriction of this technology to the high-margin therapeutic markets for 
commercial use. The authors note that in this regard hybridoma technology was never patented, 
and achieved relatively wide acceptance within a short period. They conclude that the situation 
for some of the core phage display patents is now changing rapidly, as most platform patents 
have either expired or will do so over the next few years. 
2.1.2.2 Antibody libraries 
Generally, three types of antibody libraries can be distinguished: immunised, naïve and 
synthetic (Hoogenboom & Chames, 2000; Carmen & Jermutus, 2002).The primary difference 
between these libraries is their origin. Immunised libraries are mainly derived from the immune 
repertoire of immunised animals, whereas most naïve and synthetic libraries are of human 
origin. 
Immunised libraries are created to obtain antibodies specific for a certain antigen. They are 
assembled from rearranged variable domain genes isolated from immunised donors (Clackson 
et al., 1991). 
Naïve libraries have been derived from germline immunoglobulin sequences (Söderlind et al., 
2000). Construction of naïve libraries involves relatively straightforward molecular biology 
techniques such as reverse transcription of mRNA, followed by polymerase chain reaction 
(PCR) with germline-specific primers to amplify the VH and VL gene segments from the cDNA 
template, and restriction-based cloning to incorporate the rearranged antibody segments into an 
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appropriate phagemid display vector. Finally, the vectors are transformed into E. coli cells to 
generate the antibody repertoire. 
Synthetic libraries are grafted from a single synthesised antibody molecule. Construction of 
synthetic libraries involves rearranging VH and VL gene segments in vitro and randomising the 
complementarity determining regions (CDRs) by PCR and randomised oligonucleotide primers, 
introducing varying loop lengths (Knappik et al., 2000; Brockmann et al., 2011). 
2.1.2.3 Selection of binders from phage displayed libraries 
Panning is the process for the selection and isolation of specific antibodies from antibody 
libraries by their binding activity. In principle, it involves the selection of binders/antibodies on 
the basis of their affinity. The isolation of a desired antibody generally involves repeated rounds 
of panning, with each successive round resulting in the enrichment of the desired antibody. 
Each round of antibody selection can be divided into exposing of phage to immobilised target, 
removal of nonspecific phage, and the elution and amplification of phage antibodies for the next 
round (Figure 2.1.4). 
 
Figure 2.1.4. The phage display cycle. 
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Figure 2.1.4. (continued) (A) A library of variant DNA sequences encoding peptides or proteins 
is created and cloned into phage or phagemid genomes as fusions to a coat protein gene. (B) 
The phage library displaying variant peptides or proteins is exposed to target molecules and 
phage with appropriate specificity are captured. (C) Non binding phage are washed off – 
although some non-specific binding may also occur. (D) Bound phages are eluted by conditions 
that disrupt the interaction between the displayed peptide or protein and the target. (E) Eluted 
phage are infected into host bacterial cells and thereby amplified. (G) This amplified phage 
population is in effect a secondary library that is greatly enriched in phage displaying peptides 
or proteins that bind to the target. If the bio-panning steps (B) to (E) are repeated the phage 
populated becomes less and less diverse as the population becomes more and more enriched in 
the limited number of variants with binding capacity. (G) After several (usually three to five) 
rounds of bio-panning monoclonal phage populations may be selected and analysed 
individually. Adapted from Willats (2002). 
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2.2 AIMS OF THE STUDY 
Recently, the potential health-promoting properties at the pharyngeal level of the dairy 
bacterium L. helveticus MIMLh5 were evaluated in vitro and ex vivo. The strain was proposed 
as a potential pharyngeal probiotic because of its ability to adhere to human epithelial cell lines 
and to efficiently antagonise group A streptococci on these cells (Guglielmetti et al., 2010). 
Furthermore, L. helveticus MIMLh5 appears to be a promising probable modulator of the 
immune system, which is able to reduce NF-κB activation, to influence cytokine secretion at the 
epithelial level, and potentially to skew the immune system toward a Th1 response.  
It was already demonstrated that the probiotic activity of L. helveticus can be due to the 
presence of the S-layer protein (the case of strain M92; Beganović et al., 2011). It was 
suggested that L. acidophilus NCFM is the first probiotic bacterium identified that is 
functionally involved in the modulation of dendritic cells and T cells functions and this 
immunomodulatory activity is due to its S-layer protein (Konstantinov et al., 2008). It is worth 
noting that the S-layer protein of L. acidophilus NCFM is highly similar to that of L. helveticus. 
A new study is now in progress to identify the bacterial cell components involved in the 
immunomodulatory properties of L. helveticus MIMLh5 (Taverniti et al., manuscript in 
preparation). 
For the reasons mentioned above we were interested to know whether the S-layer protein of L. 
helveticus MIMLh5, the potentially immunologically important protein, is present in food 
products, namely in Grana Padano cheese, whose natural whey starter (NWS) it was isolated 
from. 
Therefore, the aim of the present study was to determine the presence of the L. helveticus 
MIMLh5 S-layer protein in Grana Padano cheese. 
Most specifically the tasks were: 
1. To set up an efficient extraction protocol to obtain pure extracts of L. helveticus 
MIMLh5 S-layer protein. 
2. To determine the mass and the sequence of the L. helveticus MIMLh5 S-layer protein. 
3. To select the L. helveticus MIMLh5 S-layer protein-specific binders, by employing the 
antibody phage display technology. 
4. To set up an assay for the detection of L. helveticus MIMLh5 S-layer protein in Grana 
Padano cheese. 
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2.3 MATERIALS AND METHODS 
2.3.1 Bacterial strains and culture conditions 
Table 2.3.1 lists the LAB strains used in this study. L. helveticus strains were grown at 42 °C in 
MRS broth (Sigma–Aldrich, Milan, Italy) supplemented with 1 % of Tween 80 (Sigma–
Aldrich). L. acidophilus and L. delbrueckii subsp. bulgaricus were cultivated in the same 
medium at 37 °C. Escherichia coli XL1-Blue [recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F' proAB lacIqZ∆M15 Tn10 (Tetr)]] (Stratagene, Santa Clara, CA, USA) was grown in 
Luria–Bertani (LB) broth or SB medium at 37 °C, if not indicated diversely. 
 
Table 2.3.1. LAB strains included in the study. 
Species Strain Isolation source Reference 
L. helveticus MIMLh5a Grana Padano cheese 
NWS 
Guglielmetti et al., 2010 
 ATCC 15009T Emmental (Swiss) 
cheese 
Orla-Jensen, 1919 
 SLh02b Fermented milk product Unpublished 
L. acidophilus ATCC 4356T Human Efthymiou & Hansen, 1962 
 NCFMc Human intestine Sanders & Klaenhammer, 
2001 
L. delbrueckii 
subsp. bulgaricus 
ATCC 11842T Bulgarian yogurt Orla-Jensen, 1919 
a
 DiSTAM Industrial Microbiology Section Culture Collection, University of Milan (Milan, 
Italy). 
b
 Isolated from “Narine” (Vitamax-E, Yerevan, Armenia), Sacco S.r.l. Culture Collection 
(Cadorago, Italy). 
c
 Isolated from “Probactiol” (Metagenics, San Clemente, CA, USA). 
T
 Type strains from American Type Culture Collection (Manassas, VA, USA). 
 
2.3.2 Extraction and purification of S-layer protein from L. helveticus MIMLh5 
Extraction of the S-layer protein from L. helveticus MIMLh5 was performed with LiCl as 
described previously (Lortal et al., 1992; Smit et al., 2001; Johnson-Henry et al., 2007; Agave 
BioSystems, 2011). Briefly, 500 mL of an overnight culture of MIMLh5 was harvested by 
centrifugation at 3000 g for 20 min at 4 °C and washed with 1 volume of cold sterile MilliQ 
water. The cell pellet was extracted with 0.1 volume of 1 M LiCl solution for 30 min at room 
temperature in the presence of Protease Inhibitor Cocktail (Sigma–Aldrich, St. Louis, MO, 
USA) with slight agitation and centrifuged. The cell pellet was then extracted with 0.1 volumes 
of 5 M LiCl solution for 1 h at room temperature in the presence of Protease Inhibitor Cocktail 
and centrifuged once more. The supernatant was filtered through a 0.2 µm filter and 
exhaustively dialysed for 36 h at 4 °C against distilled water using 12000 kDa cut-off 
membranes (Sigma–Aldrich), which were prepared for dialysis by boiling in 2 % of NaHCO3 
and 1 mM EDTA solution. Each time changing the water 0.001 % of Protease Inhibitor 
Cocktail was added. The dialysate was collected and centrifuged at 20000 g for 20 min at 4 °C. 
The supernatant was removed and the pellet resuspended in several millilitres of sterile MilliQ 
water, shelf frozen and freeze dried. Protein concentration was determined by using the 
Bradford microassay method using bovine serum albumin (BSA) as a standard. Protein purity 
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was determined by sodium dodecylsulphate–polyacrylamide gel electrophoresis (SDS–PAGE) 
and RP–HPLC analysis. 
2.3.3 SDS–PAGE 
S-layer protein and total bacterial lysates were resuspended in SDS–PAGE (Laemmli) sample 
buffer (31.25 mM Tris pH 6.8, 12.5 % glycerol, 1 % SDS, 0.005 % bromophenol, 2.5 % β-
mercaptoethanol), boiled for 5 min, and separated on 10 % SDS–PAGE in TRIS–glycine–SDS 
buffer on Mini-PROTEAN 3 system (Bio-Rad Italia, Milan, Italy). Gels were stained with 
Coomassie brilliant blue G-250 (Sigma–Aldrich). 
2.3.4 RP–HPLC of S-layer protein 
Samples were analysed by RP–HPLC on Waters Alliance 2695 instrument (Waters, 
Vimodrone, Italy). Protein was separated at 40 °C on a PLRP-S column (2.1 mm i.d., 5 µm, 300 
Å, Polymer Laboratories Ltd, Church Stretton, UK). The eluents used for the separation were: 
solvent A, 0.1 % TFA in MilliQ-treated water, and solvent B, 0.1 % TFA in acetonitrile. The 
linear elution gradient expressed as the solvent B proportion was as follows: 0 min, 25 %; 0 to 5 
min, 25 %; 5 to 35 min, 25 to 55 %; 35 to 36 min, 55 to 95 %; 36 to 38 min, 95 %; 38 to 39 
min, 95 to 25 % (run–to–run time, 40 min). Protein was eluted at a flow rate of 0.2 mL min-1 
and monitored at 210 nm with Waters 2996 Photodiode Array Detector (Waters). 
2.3.5 Evaluation of immunomodulatory activity of L. helveticus MIMLh5 S-layer 
protein 
The immunomodulatory activity of L. helveticus MIMLh5 S-layer protein was determined 
according to the method described previously (chapter 1.3.7) with some modifications. 
Recombinant Caco-2 cells were cultured in 24-well plates in presence of 50 µg mL-1 zeocin 
until the confluence. Cell monolayers (approximately 3 × 105 cells well-1) were carefully 
washed with PBS buffer (pH 7.4), and 0.5 mL of fresh EMEM medium, containing 100 mM of 
HEPES (pH 7.4) and 100 µg of the L. helveticus MIMLh5 S-layer protein, was added. Caco-2 
cells were stimulated and NF-κB activation was determined as described above. All samples 
were analysed in duplicate in at least three independent experiments. 
2.3.6 Determination of molecular mass of S-layer protein by mass spectrometry 
For liquid chromatography–mass spectrometry (LC–MS) analysis, S-layer protein was 
resuspended in MilliQ water or dissolved in 8 M urea. Mass determination analysis was 
performed on Waters Acquity UPLC instrument (Waters, Vimodrone, Italy) connected to a Q-
Tof micro mass spectrometer (Waters) equipped with an orthogonal electrospray source (Z-
spray). Protein was separated at 40 °C on Acquity UPLC BEH300 C4 column (2.1×150 mm, 
1.7 µm, Waters). The eluents used for the separation were: solvent A, 0.1 % formic acid in 
MilliQ-treated water, and solvent B, 0.1 % formic acid in acetonitrile. The linear elution 
gradient expressed as the solvent B proportion was as follows: 0 min, 25 %; 0 to 4.78 min, 25 
%; 4.78 to 22.78 min, 25 to 55 %; 22.78 to 23.38 min, 55 to 95 %; 23.38 to 24.58 min, 95 %; 
24.58 to 25.18 min, 95 to 25 % (run–to–run time, 27 min). Protein was eluted at a flow rate of 
0.2 mL min-1 and monitored at 210 nm with Acquity UPLC Photodiode Array Extended λ 
Detector (Waters). Mass spectra acquisition was performed in positive ion mode. The optimised 
mass spectrometry conditions were: capillary voltage 3200 V, source temperature 100 °C, and 
cone voltage 45 V. The electrospray ionisation (ESI) gas was nitrogen. The Tof analyser 
collected data between m/z 500 and 2000. The acquired MS spectrum was analysed with the 
MassLynx 4.1 software (Waters). MS data were processed using MaxEnt 1 algorithm. 
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2.3.7 Determination of S-layer coding gene sequence from L. helveticus MIMLh5 and 
its analysis 
Determination of S-layer coding gene was performed by PCR using specific primers: SLY ex F, 
CTGCAACTGCTATGCCTGT and SLY ex R, ATACGCTTAGTACCATCGA on the DNA 
extracted from the isolate according the standard procedure (Sambrook et al., 2001). The PCR 
conditions were as follows: predenaturation at 94 °C for 2 min, 35 cycles at 94 °C for 45 s, 56 
°C for 45 s, 72 °C for 1.5 min, and a single final extension at 72 °C for 7 min. All amplification 
reactions were performed in a MyCycler thermal cycler (Bio-Rad Italia, Milan, Italy). PCR 
products were purified using PCR Clean-Up Kit (MO BIO Laboratories, Carlsbad, CA, USA) 
and sequenced with the dideoxy chain–termination principle (Sanger et al., 1977) employing 
Applied Biosystems Big Dye Chemistry v3.1 (Applied Biosystems, CA, USA). 
Homology searches of the databases were done with the BLAST service at the National Center 
for Biotechnology Information (Altschul et al., 1990). Sequence alignments were performed 
using MEGA 5 (Tamura et al., 2011) and Align X module of Vector NTI Advance™ 11 
(Invitrogen, Finland). 
The isoelectric point and the theoretical molecular weight of the protein were calculated with 
Compute pI/Mw tool from ExPASy (Gasteiger et al., 2005). 
2.3.8 Coating procedure 
S-layer protein was coated on microtiter wells by passive adsorption. Lyophilised S-layer 
protein was dissolved in 5 M LiCl solution in mQ water up to 50 µg mL-1 concentration or later 
diluted up to 10 µg mL-1 with 5 M LiCl. MaxiSorpTM and PolySorpTM microtitration plates in 
12-strip well formats were from Nunc (Roskilde, Denmark). The normal coating procedure for 
S-layer protein, the preparation of the control plate, is briefly described below. S-layer protein 
was diluted in the coating buffer (100 mM TRIS–HCl, pH 9.0) to the final concentration 5.0 µg 
mL-1 (or 1.0 µg mL-1). Then 200 µL of the coating solution was dispensed into each well, 
giving 1 µg (for pannings) and 0.2 µg (for immunoassays) S-layer protein per well. The plates 
were closed in a humidified box and incubated overnight at room temperature (approximately 
25 °C). Then the plates were washed twice in a DELFIA Platewash (Perkin-Elmer Life 
Sciences, Turku, Finland) with DELFIA Wash Solution supplemented with Tween 20 (Merck, 
Hohenbrunn, Germany) to the final concentration 0.05 %. After washing, 250 µL of saturation 
solution (50 mM Tris–HCl, pH 7.0; 150 mM NaCl; 0.05 % NaN3; 6 % D-sorbitol) with BSA 
(0.2 % bovine serum albumin fraction V powder; γ-globulin free, Sigma–Aldrich) or skim milk 
(1 %) was added per well. The plates were saturated overnight at room temperature 
(approximately 25 °C). The saturation solution was aspirated in a DELFIA Platewash and the 
plates were dried (25 °C, under the laminar hood) for 4 h. Finally the plates were packed with 
moisture adsorbent into an aluminium zip-bag and stored dry at 4 °C. The control plates were 
prepared coating microtiter wells only with saturation solution, containing BSA or skim milk. 
2.3.9 Synthetic human antibody libraries, vectors and helper phage 
Synthetic human phage displayed scFv protein and hapten MolBind libraries (total diversity, 
1.40 × 1010) were provided by the Department of Biotechnology, University of Turku (Turku, 
Finland) cloned into pEB32x phagemid. The libraries are based on a single human framework. 
The framework gene is composed of a single human VLkappa and a single VH chain sequence. 
Chains were diversified by Kunkel mutagenesis at positions in the antigen binding site (CDR 
loops) that make contact to antigens (proteins and haptens, respectively), and subjected to 
affinity maturation by VL shuffling (Brockmann et al., 2011). The scFv fragments comprise a 
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single polypeptide with the VH and VL domains attached to one another by a flexible 20 amino 
acid long glycine–serine linker. 
The vectors used are shown in Figure 2.3.1. 
 
Figure 2.3.1. Phagemid pEB32x (A) and expression vector pLK06H for 6×His-tagged bacterial 
alkaline phosphatase (PhoA) fusions (B). 
 
Phagemid vector pEB32x was used for monovalent phage display with helper phage VCS M13 
(Stratagene, La Jolla, CA, USA). It conferred chloramphenicol resistance. Vector pLK06H 
(containing β-lactamase encoding gene (bla) for ampicillin resistance) was used for screening 
antibody clones. In this vector scFv was cloned through SfiI restriction sites and expressed as 
fused to bacterial alkaline phosphatase (PhoA). His-tag from this vector allows affinity 
purification using Ni-NTA matrix. Both vectors had IPTG inducible Lac promoter. Protein was 
directed to periplasm of E. coli by pelB signal sequence. Vectors pEB32x and pLK06H are 
derivatives of pAK200 and pAK600, respectively (Krebber et al., 1997). They were kindly 
provided by the Department of Biotechnology, University of Turku, Finland. Primer pAKfor 5’-
TGAAATACCTATTGCCTACG-3’ was used for sequencing of scFv fragment from the vector 
pLK06H. 
2.3.10 Panning on microtiter wells 
Panning is the process for the selection and isolation of specific antibodies by their binding 
activity. S-layer coated microtiter wells were panned with a mixture 1 : 1 of pEB32x scFv 
hapten MolBind and pEB32x scFv protein MolBind phage libraries (Brockmann et al., 2011). 
This phage library mix (2.5 × 1012 cfu mL-1, dilution in TBT-0.05) was first incubated in a well 
(200 µL well-1) not coated with S-layer protein for 1 h at room temperature with slow shaking 
(Delfia® plateshake, low mode, Perkin-Elmer Life Sciences, Turku, Finland), upon which the 
unbound fraction was transferred to S-layer-coated wells. After 2 h (for the first panning) and 1 
h (for the subsequent pannings) of incubation, the wells were washed 3 times (for the first 
panning) and 4 times (subsequent panning) with TBT-0.1, then 1 time with TBS-0.1 % Tween 
20. The bound phages were then eluted with 200 µL of trypsin solution (60 µg mL-1 in TBS) for 
15 min at room temperature and after neutralised with 1/10 volume of trypsin inhibitor (1 mg 
mL-1 in TBS). 
The eluate was amplified by infection to E. coli XL1-Blue. The phages were purified by 
precipitation with PEG-8000 (16 % w/v)/NaCl (12 % w/v) on ice for 10 min and titrated using 
A B 
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LB agar plates with tetracycline (10 µg mL-1) and chloramphenicol (25 µg mL-1). The titrated 
phage was then diluted to 1 × 1011 cfu mL-1 in TBT-0.05 and applied as the input phage for 
subsequent pannings. 
2.3.11 Screening for the binding specificity of phage antibodies to purified S-layer 
protein 
To screen for binding specificity of phage library stocks (scFv-p3 fusions), they were 
diluted 1:10000 in Red Kaivogen Assay Buffer (Kaivogen, Turku, Finland) and analysed by 
DELFIA® time-resolved fluorescence immunoassay. In the assay, an antigen, the S-layer 
protein, was firstly bound to MaxiSorpTM and PolySorpTM microtitration wells, 0.2 µg well-1, as 
indicated above. Then phage samples were incubated for 1 h in slight agitation (DELFIA® 
plateshake, low mode; Perkin Elmer Life Sciences, Turku, Finland) and after washing the plate 
Eu-N1-labelled anti-phage Mab (University of Turku, Turku, Finland) was bound. Time-
resolved fluorescence signal of Eu3+ was measured with Victor 1420 multilabel counter (Perkin 
Elmer Life Sciences, Turku, Finland) after 10 min development with Delfia enhancement 
solution. 
To screen for binding specificity of individual phage antibody clones, the enriched library 
was cloned into vector pLK06H (through SfiI restriction sites), which expresses scFv as a fusion 
to PhoA and 6×His-tag. Individual clones were inoculated in SB medium (0.05 % glucose, 10 
µg mL-1 tetracycline, 100 µg mL-1 ampicillin) onto a 96-well V-bottom culture plate (Corning 
Life Sciences, Pittston, USA) covered with a breathable sealing tape (Nunc, Roskilde, 
Denmark). Clones were grown for 4–6 h at 37 °C, 700 rpm, 70 % humidity. The cells induced 
with 100 µM IPTG and incubated overnight at 26 °C, 700 rpm. For periplasmic extraction, 1/5 
volume of freshly prepared 5× lysis buffer (350 mM TRIS, pH 8.0, 10 mM EDTA, 10 mg mL-1 
lysozyme) was added. Plates were incubated 10 min at 30 °C, 700 rpm and subsequently 
centrifuged 10 min at 4 °C, 3220 g. Supernatants were analysed by alkaline phosphatase (AP) 
chromogenic ELISA assay. In the assay, samples, diluted 1:10 with Red Kaivogen Assay Buffer 
were incubated for 1 h in the microtitration wells, coated with S-layer protein. After washing 
the plate 4×, substrate, para-nitrophenyl phosphate (pNPP) solution (50 mM TRIS, pH 9.0, 200 
mM NaCl, 1 mM MgCl2, 5 mM pNPP,) was added. Absorbance of p-nitrophenolate at 405 nm 
was measured with Victor 1420 multilabel counter (Perkin Elmer Life Sciences, Turku, 
Finland) after 1 h of colour development. A clone was considered to be positive if the specific 
signal and relative absorbance (A405S-layer-coated well – A405S-layer-uncoated well) were 
above 0.5 (A405). 
The test of specificity of the L. helveticus MIMLh5 S-layer protein-binding clones was based on 
phage binding to different S-layer containing LAB strains in suspension, and it was performed 
as indicated bellow. 
2.3.12 Screening for the binding specificity of phage antibodies to S-layer protein-
containing LAB strains 
To screen for the MIMLh5 strain S-layer-specific phage antibodies, the MIMLh5 S-layer-
positive scFv binder clones were inoculated in 5 mL of SB medium (0.05 % glucose, 10 µg mL-
1
 tetracycline, 100 µg mL-1 ampicillin) in culture tubes and cultivated at 37 °C with 300 rpm 
shaking to OD (600 nm) 0.8. The cultures were induced with 100 µM IPTG and grown further 
overnight at 26 °C with 250 rpm shaking. Cells were harvested by centrifugation 3220 g for 10 
min at 4 °C. The pellet was resuspended in 1 mL (i.e. 5× concentrated) of modified Kaivogen 
Assay Buffer [mKAB, 50 mM TRIS–HCl, pH 7.5, 0.9 % NaCl, 0.01 % Tween-40, 0.5 % BSA 
(fraction V powder, Sigma–Aldrich, St. Louis, MO, USA)]. Cells were disrupted by sonication 
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and by two subsequent freeze (–70 °C) and thaw cycles. The lysate was centrifuged 15700 g for 
5 min at 4 °C and the supernatant containing soluble anti-S-layer-scFv-PhoA binders was 
aliquoted and stored at –20 °C before AP chromogenic immunoassay in suspension. In the 
assay, lactobacilli cells were grown over night in MRS medium, harvested by centrifugation 
3200 g, 5 min at 4 °C, resuspended in mKAB and “discharged” for 30 min at bacterial growth 
temperature. Then cell pellets were washed with mKAB and resuspended in the same buffer up 
to approximately 109 cells mL-1. 100 µL of cell suspensions were aliquoted (approximately 108 
cells/tube). The number of cells was selected empirically before by testing different cell 
concentrations (e.g. 108, 109 cells mL-1). 100 µL of 5× diluted in mKAB lysates, containing 
anti-S-layer-scFv-PhoA binders, were added. LAB cell and scFv-PhoA binder suspensions were 
incubated for 1 h at room temperature in rotational agitation (13 rpm, Grant-bio PTR-30 rotator, 
Grant Instruments, Cambridge, UK). After washing 2× (the number of washes was selected 
empirically) with cold mKAB, a substrate, pNPP, solution was added and suspension was 
incubated at room temperature for 2 hours in rotational agitation (13 rpm). Cells were 
precipitated by centrifugation at 15700 g, 5 min, 4 °C and the absorbance of p-nitrophenolate in 
the supernatant was measured as described above. A clone was considered to be a positive 
binder to S-layer protein if the specific signal was above 3.0 or the relative absorbance 
(A405MIMLh5 – A405Lb11842) was above 1.0 (OD405). 
2.3.13 Preparation of anti-S-layer binder (anti-S-layer scFv-PhoA-6×His fusion) extracts 
for Western blotting 
Anti-S-layer-scFv-PhoA-6×His fusion extracts were prepared under native conditions as 
indicated below. Briefly, cultures of 40 mL SB (10 µg mL-1 tetracycline, 100 µg mL-1 
ampicillin, 0.05 % glucose) were inoculated with precultures to OD (600 nm) 0.05 and grown at 
37 °C with 300 rpm shaking to OD (600 nm) 0.8. The cultures were induced for periplasmic 
expression of anti-S-layer-scFv-PhoA-6×His binders with 100 µM IPTG and grown further 
overnight at 26 °C with 250 rpm shaking. Cells were harvested by centrifugation 3220 g for 15 
min at 4 °C. The pellet was resuspended in 1.2 mL of Lysis Buffer (20 mM sodium phosphate, 
500 mM NaCl, pH 7.4) giving the final volume of approximately 1.5 mL. 2 mg mL-1 of 
lysozyme, 5 mM of MgCl2, 112.5 U of DNase (Ambion, Applied Biosystems, Espoork, 
Finland), 1 mM PMSF were added. Suspensions were incubated 30 min at room temperature in 
rotational agitation and set on ice. Samples were further sonicated on ice and centrifuged 15700 
g for 5 min at 4 °C on table top centrifuge. The supernatant, soluble fraction, was filtered 
through 0.2 µm ∅ syringe filter, pipetted to fresh tubes and stored at –20 °C. 
2.3.14 Preparation of LAB total protein extracts for Western blotting 
For preparation of total protein extracts, LAB cells were cultivated overnight in MRS medium, 
harvested by centrifugation 3220 g for 15 min at 4 °C. Cell pellet was washed, resuspended in 
cold PBS buffer, containing 1 mM PMSF and subjected to disruption by French Press E 1061 
machine (Constant Systems, Daventry, UK) as indicated by manufacturer. Briefly, 
Lactobacillus spp. cells were resuspended in cold PBS buffer, containing 1 mM PMSF at a ratio 
1 : 5 (wet weight of biomass vs. volume of resuspension buffer) and subjected to the pressure of 
35000 psi for 3 times consecutively. Cell lysate was collected, aliquoted and stored at –70 °C 
before loading on polyacrylamide gel. For Western blotting analysis, 120 µg of total protein 
extract (per lane; concentration measured according A280) was boiled for 5 min in SDS–PAGE 
(Laemmli) sample buffer (31.25 mM Tris pH 6.8, 12.5 % glycerol, 1 % SDS, 0.005 % 
bromophenol blue, 2.5 % β-mercaptoethanol) and separated on 10 % SDS–PAGE. 
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2.3.15 Detection of L. helveticus MIMLh5 S-layer protein by Western blotting 
For denaturing conditions, proteins from SDS–PAGE gels were transferred to polyvinylidene 
fluoride (PVDF) membrane (Hybond-P, Amersham Biosciences, Buckinghamshire, UK) at a 
constant voltage of 15 V at room temperature for 15 min on a Trans-Blot SD Semi-Dry 
Transfer Cell Module (Bio-Rad Laboratories, Richmond, CA, USA) in 3-[cyclohexylamino]-1-
propanesulfonic acid (CAPS) electroblotting buffer system (10 mM CAPS, pH 11, 10 % 
methanol). For native conditions, Lactobacillus spp. total protein extracts were loaded as dots 
on the membrane and let to be absorbed passively. Membranes were blocked for at least 1 h in 5 
% (w/v) non-fat dry milk in TBS (TRIS-buffered saline, pH 7.5) at room temperature. Further, 
blotting was done using anti-S-layer binder (anti-S-layer scFv-PhoA-6×His fusion) extracts in 
1:200 dilution (in TBS with 0.05 % Tween20) as primary antibody (incubation overnight at 8 
°C in rotational agitation) and horse radish peroxidase (HRP)-conjugated anti-His mouse 
monoclonal IgG1 (5Prime, VWR International, Helsinki, Finland) in 1:2000 dilution (in TBS 
with 0.05 % Tween20) as secondary antibody (incubation for 1 h at room temperature in 
rotational agitation). The membrane was visualised (chromogenic detection) with CN/DAB 
Substrate Kit (Thermo Scientific, Rockford, USA) with two consecutive substrate exposures. 
2.3.16 Preparation of Grana Padano cheese samples for Western blotting 
Samples from different stages of Grana Padano cheese maturation are listed in Table 2.3.2. 
They were kindly supplied by the Consorzio Tutela Grana Padano with the following 
specifications: dates of production and sample collection, registration number, indicating the 
manufacturer and the production site. 
 
Table 2.3.2. Grana Padano samples used for the study. 
Sample Age Production date Sampling date 
Registration 
No. 
NWS N/A  01.06.2011. MN437 
Curd 48 hours 01.06.2011. 01.06.2011. MN437 
Grana Padano “cheese”* 2.0 months 03.2011. 30.05.2011. PC540 
 3.5 months 15.02.2011. 31.05.2011. MN401 
 3.6 months 13.02.2011. 01.06.2011. MN437 
 4.0 months 01.2011. 30.05.2011. PC540 
 5.0 months 11.2010. 27.04.2011. PD711 
 5.0 months 12.2010. 25.05.2011. MN410 
 5.0 months 12.2010. 25.05.2011. VI610 
N/A, not applicable 
*
 GP can be named as cheese only from the 9th month of ripening (Consorzio Tutela Grana 
Padano, 2011). For this reason samples below 9 months are indicated in quotation-marks. 
 
Samples were lyophilised. Skimmed milk powder was used as a negative control. PageRulerTM 
Plus Prestained Protein Ladder (Fermentas, Vilnius, Lithuania) and lyophilised S-layer protein 
of L. helveticus MIMLh5 were used as positive controls. Then, samples were resuspended in the 
extraction buffer up to the concentration of 100 mg of lyophilisate per 1 mL of extraction 
buffer. The following extraction buffers were used: 5 M LiCl, 5 M urea, 1 % SDS, 4 % SDS, 
PBS buffer, 6 M GuHCl, 5 M LiCl with 8 M urea (ratio 1:1), 8 M urea. Extractions were 
performed at room temperature for 1 h in rotational agitation (Grant-bio PTR-30 rotator, Grant 
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Instruments, Cambridge, UK) except those of SDS, which were done at room temperature for 1 
h as well as at 100 °C for 5 min. Subsequently, samples were centrifuged 5000 g at 40 °C for 30 
min and freezed at –20 °C. If necessary, the solidified upper fat phase was removed with a 
wooden toothpick and the thawed intermediate phase (between precipitate of insoluble material 
(if present) and the upper fat) was taken for Western blottings. 
2.3.17 Detection of S-layer protein in cheese samples by Western blotting 
10–20 µL of cheese extracts (the maximum volume being absorbed by the membrane) were 
loaded as dots on methanol-activated polyvinylidene fluoride (PVDF) membrane (Immuno-
BlotTM PVDF Membrane, absorbance rate 0.2 µm, Bio-Rad Laboratories, Richmond, CA, USA) 
and run at a constant voltage of 4 V (approximately 100 mA) at room temperature for 1 h on a 
Trans-Blot SD Semi-Dry Transfer Cell Module (Bio-Rad Laboratories, Richmond, CA, USA) 
in 3-[cyclohexylamino]-1-propanesulfonic acid (CAPS) electroblotting buffer system (10 mM 
CAPS, pH 11, 10 % methanol). Membranes were blocked for at least 1 h in 5 % (w/v) non-fat 
dry milk in TBS (TRIS-buffered saline, pH 7.5) at room temperature. Blotting was done using 
anti-S-layer binder (anti-S-layer scFv-PhoA-6×His fusion) extracts in 1:200 dilution (in TBS 
with 0.05 % Tween-20) as primary antibody (incubation overnight at 8 °C in rotational 
agitation) and HRP-conjugated anti-His mouse monoclonal IgG1 (5Prime, VWR International, 
Helsinki, Finland) in 1:2000 dilution (in TBS with 0.05 % Tween-20) as secondary antibody 
(incubation for 1 h at room temperature in rotational agitation). The membrane was visualised 
(chromogenic detection) with 4-chloro-1-naphthol/3,3’-Diaminobenzidine (CN/DAB) Substrate 
Kit (Thermo Scientific, Rockford, USA) with two consecutive substrate exposures. 
2.3.18 Statistical analysis 
The significance of the results in the experiments for the evaluation of immunomodulatory 
activity of L. helveticus MIMLh5 S-layer protein and screening for the binding specificity of 
phage antibodies was analysed by unpaired heteroscedastic Student’s t test with two-tailed 
distribution. Differences of P < 0.05 were considered to be significant. 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Extraction and purification of L. helveticus MIMLh5 S-layer protein 
A generally employed method for the removal of S-layer protein from cell surfaces, LiCl 
extraction, was applied for the isolation of the S-layer protein from L. helveticus MIMLh5. It 
allowed obtaining S-layer protein extracts from different bacterial growth phases: early 
exponential (1 point, OD600=0.5), mid-exponential (2 points, OD600=1.5 and 2.5), and stationary 
phase (2 points, OD600=4.0 and 5.0) (Figure 2.4.1A, indicated by arrows). The purity of the 
extracts was determined from the electrophoregrams of the SDS–PAGE analysis. The obtained 
gel demonstrates a single well defined band of approximately 45000 Da, corresponding to the 
S-layer protein of the analysed strain (Figure 2.4.1B; electrophoregram of the S-layer protein 
from mid-exponential growth phase (point of OD600=2.5) is presented as an example). The 
purity of the extracted S-layer protein was confirmed by RP–HPLC analysis (Figure 2.4.1C). 
 
Figure 2.4.1. Growth curve of L. helveticus MIMLh5 (A): arrows indicate growth phases the S-
layer protein was extracted from. SDS–PAGE (B) and the RP–HPLC profile (C) of the S-layer 
protein from bacterial mid-exponential growth phase (OD600=2.5). 
 
It was demonstrated that the purity of the extracted protein does not depend on the bacterial 
growth phase: SDS–PAGE and RP–HPLC analyses demonstrated one main band and the one 
main HPLC peak, respectively. 
2.4.2 Evaluation of in vitro immunomodulatory activity of L. helveticus MIMLh5 S-
layer protein 
L. helveticus MIMLh5 S-layer protein was tested in vitro for a potential immunomodulatory 
activity. In this regard, it has been evaluated its capability to modulate the activation of 
transcription factor NF-κB in Caco-2 cells: in basal conditions as well as in the presence of pro-
inflammatory stimulus of interleukin (IL)-1β. In basal conditions, the obtained results 
demonstrated a significant decrease of the bioluminescence, i.e. the activation of NF-κB, with 
S-layer samples from all bacterial growth phases (Figure 2.4.2A). 
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Figure 2.4.2. Effects of S-layer protein extracts from different L. helveticus MIMLh5 growth 
phases (indicated by OD600) on recombinant Caco-2 cells in basal conditions (A) and in the 
presence of co-stimulation with IL-1β (B). Luciferase activity is expressed as percentual change 
in relative luminescence units, assuming the control as 100 %. Control, Caco-2 incubated 
without S-layer protein. The values are the means (± standard deviation) of at least three 
independent experiments conducted in duplicate. An asterisk (*) indicates statistically 
significant differences compared to control. 
 
Further, the anti-inflammatory activity of all S-layer extracts was tested. For this reason, 
recombinant Caco-2 cells were co-stimulated with S-layer protein extracts from different 
bacterial growth phases and IL-1β, a prototypical pro-inflammatory cytokine that plays a 
central role in the amplification of inflammatory cascade. The addition of 2 ng mL-1 of IL-1β to 
Caco-2 culture medium caused nearly a twofold increase of NF-κB activity after 4 h incubation. 
After stimulation by IL-1β, all five S-layer extracts significantly reduced the NF-κB activation, 
while the control (EMEM medium with IL-1β, but without S-layer) did not have any significant 
effect (Figure 2.4.2B). 
2.4.3 Determination of the L. helveticus MIMLh5 S-layer protein molecular mass 
Determination of L. helveticus MIMLh5 S-layer protein size was performed by SDS–PAGE. It 
was calculated to be approximately 45 kDa (Figure 2.4.1B). To specify the molecular mass of 
the protein, an electrospray ionisation-mass spectrometry analysis after fractionation in ultra 
performance liquid chromatography (UPLC–ESI-MS) was performed. According to ESI-MS 
analysis the molecular mass of L. helveticus MIMLh5 S-layer protein was determined to be 
43853 Da (Figure 2.4.3) in agreement with the size of the other known S-layer proteins from the 
genus Lactobacillus (Åvall-Jääskeläinen & Palva, 2005). 
O
D
~
0.
5
O
D
~
1.
5
O
D
~
2.
5
O
D
~
4.
0
O
D
~
5.
0
Co
n
tro
l
0
20
40
60
80
100
120
Ch
a
n
ge
 
o
f b
io
lu
m
in
e
sc
e
n
ce
 
(%
)
*, P <0.01
*
*
*
*
*
O
D
~
0.
5
O
D
~
1.
5
O
D
~
2.
5
O
D
~
4.
0
O
D
~
5.
0
Co
n
tro
l
0
20
40
60
80
100
120
Ch
a
n
ge
 
o
f b
io
lu
m
in
e
sc
e
n
ce
 
(%
)
*
*
*
*
*
*, P <0.01A B 
2.4 Results and Discussion 
 
60 
Figure 2.4.3. ESI-MS spectrum of the L. helveticus MIMLh5 S-layer protein and reconstructed 
mass spectrum indicating an average mass value of 43853 Da. 
2.4.4 Prediction of the L. helveticus MIMLh5 S-layer protein sequence 
PCR amplification with specific primers was used to amplify the S-layer protein gene from the 
genome of L. helveticus MIMLh5. A single PCR product was obtained from L. helveticus 
MIMLh5 chromosomal DNA (data not shown). The theoretical molecular mass obtained from 
the deduced amino acid sequence (Table 2.4.1) of the L. helveticus MIMLh5 S-layer protein 
was 46798 Da (with signal peptide) and 43853 Da (without signal peptide). The later 
corresponded to the molecular mass obtained by mass spectrometry analysis. 
Table 2.4.1. Amino acid composition of the S-layer protein of L. helveticus MIMLh5. 
Amino acid Quantity Molar ratio (%) 
Ala (A)H 45 11.0 
Arg (R) 5 1.2 
Asn (N) 38 9.3 
Asp (D) 25 6.1 
Cys (C) 0 0.0 
Gln (Q) 10 2.4 
Glu (E) 9 2.2 
Gly (G) 24 5.9 
His (H) 3 0.7 
Ile (I)H 22 5.4 
Leu (L)H 12 2.9 
Lys (K)  43 10.5 
Met (M)H 3 0.7 
Phe (F)H 11 2.7 
Pro (P)H 13 3.2 
Ser (S) 30 7.3 
Thr (T) 51 12.4 
Trp (W)H 0 0.0 
Tyr (Y) 23 5.6 
Val (V)H 43 10.5 
Total 410 100 
H
 hydrophobic amino acids (according Åvall-Jääskeläinen & Palva, 2005) 
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The S-layer protein of L. helveticus MIMLh5 has a high content of hydrophobic amino acid 
residues (36.3 %), which is a typical feature for all S-layer proteins. As observed for other S-
layer proteins (Åvall-Jääskeläinen & Palva, 2005), also the MIMLh5 S-layer has a low content 
of sulphur-containing amino acids (0.7 %), which derives from methionine residues. A 
characteristic feature for all S-layer proteins, including the ones derived from Lactobacillus, is a 
high percentage of amino acids with hydroxyl groups (serine and threonine): 19.7 % in a case of 
MIMLh5 S-layer. From the basic amino acids, the lysine content of S-layer proteins is usually 
relatively high, 10 %, and this can also be noted for L. helveticus MIMLh5 S-layer protein (10.5 
%). 
The isoelectric point (pI) of the protein is high due to the presence of positively charged amino 
acid residues: it was calculated to be 9.39, which corresponds to the pI of the other known S-
layer proteins from the genus Lactobacillus (pI 9.35 to 10.4, Åvall-Jääskeläinen & Palva, 2005). 
The protein is weakly soluble in aqueous solutions and is completely soluble in high ionic 
strength solutions such as 5 M LiCl and 8 M urea. 
The overall sequence similarity of all up to date sequenced S-layer proteins within the genus 
Lactobacillus is very small. However, similarities between the S-layers of L. helveticus and L. 
acidophilus exist (Åvall-Jääskeläinen & Palva, 2005). A similarity search using the deduced 
amino acid sequence of the L. helveticus MIMLh5 S-layer protein was performed. It revealed 
rather high overall sequence similarity (84 % of consensus positions) with other S-layers of L. 
helveticus and three S-layer proteins of L. acidophilus. The dendrogram shows the presence of 
tree types of S-layer proteins within the species L. helveticus (Figure 2.4.4). The first type 
comprehends S-layer protein of L. helveticus MIMLh5 as well as the S-layer proteins of L. 
acidophilus. A high level of sequence homology was demonstrated at the N-terminal and C-
terminal parts that are supposed to be responsible for membrane anchoring and self-assembly, 
respectively (Figure 2.4.5). These results are in agreement with previously published data about 
L. helveticus S-layer proteins (Gatti et al., 2005). 
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Figure 2.4.4. Neighbour-joining dendrogram generated from the ClustalW alignment of the 
mature S-layer proteins most closely related to the S-layer protein of L. helveticus MIMLh5. 
Database accession numbers are indicated in parentheses. Bar indicates substitution/site. 
Bootstrap values of the main internodes (500 replicates) are shown. Proteins used in this study 
are circled. 
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2.4.5 Selection and basic characterisation of scFv antibodies against L. helveticus 
MIMLh5 S-layer protein from phage displayed libraries 
ScFv antibodies for L. helveticus MIMLh5 S-layer protein were obtained by phage display 
technology. 
2.4.5.1 Immobilisation of L. helveticus MIMLh5 S-layer protein 
The first step of scFvs selection against L. helveticus MIMLh5 S-layer protein was the purified 
protein immobilisation on the surface, i.e. coating of microtiter wells. 
Two different surfaces, MaxiSorpTM and PolySorpTM, were employed for coating. MaxiSorpTM 
and PolySorpTM surfaces were developed by Nunc (Roskilde, Denmark) for immunology 
assays. These surfaces are different in their physicochemical properties. The MaxiSorpTM 
surface is a modified, highly charged polystyrene surface with high affinity to molecules with 
polar or hydrophilic groups. The surface has a high binding capacity for proteins. The 
PolySorpTM surface is more hydrophobic than the MaxiSorpTM surface. It has high affinity to 
molecules of a more hydrophobic character. This surface is particularly suited to non-protein 
antigens. However, the S-layer protein of MIMLh5 contains 36.3 % of amino acids with 
hydrophobic side chains (Table 2.4.1). For this reason, also the PolySorpTM surface was used in 
our experiments. 
For S-layer protein coating we selected passive coating strategy. This strategy was supposed to 
be advantageous because of the exceptional property of the S-layer protein to self-assembly on 
surfaces in its native conformation (Agave BioSystems, 2011; Horejs et al., 2011). 
The insolubility of the protein in aqueous solutions introduced additional difficulties in coating 
procedure, as for coating the protein should be soluble. For this reason, we completely 
solubilised the protein in LiCl and then diluted with coating buffer. 
For coating we selected a buffer system, which has a pI similar to that of the S-layer protein 
(9.39) and is compatible with LiCl-solubilised proteins: Tris–HCl buffer of pH 9.0 
Subsequently, plates were blocked with two different blocking agents: milk (the traditional 
blocker used in phage selection) and bovine serum albumin (BSA, thinking to avoid the further 
possible cross-reactions of selected binders, which were supposed to be applied on milk-derived 
products). 
There are no means to monitor the binding efficacy to the microtiter well of unknown target in 
the coating stage. Therefore, the comparison of binding efficacy to two different surfaces, 
MaxiSorpTM and PolySorpTM, could be performed only in the subsequent stages, after the 
preselection of S-layer protein binders. 
2.4.5.2 Selection, isolation and testing of binder pool 
Selection and isolation. A mix of two synthetic phage display MolBind libraries pEB32x 
(scFv-p3 fusions), protein-directed and hapten-directed, was used for the selection of scFvs 
against the S-layer protein. 
The pre-selection step on BSA-blocked plates without antigen (S-layer protein) was used to 
remove the phage binders, which showed specificity to the blocker as well as to the surface 
plastics. 
Three rounds of panning were performed. The panning scheme is presented in Figure 2.4.6. 
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Figure 2.4.6. Panning scheme for the selection of scFvs, specific for the L. helveticus MIMLh5 
S-layer protein, from pEB32x-scFv MolBind libraries. 
 
The first panning was done on MaxiSorpTM and PolySorpTM plates, blocked with BSA. The 
second round was performed on MaxiSorpTM and PolySorpTM plates, blocked with milk, 
thinking to avoid the pre-selected binders at the first round, specific to milk proteins. The third 
round was done on MaxiSorpTM and PolySorpTM plates, blocked with milk or BSA, in order to 
have the maximal variety of obtained binders. 
To monitor the enrichment of the panning process, input and output phages of each round were 
titrated (Table 2.4.2). The titre of the eluted phages dropped after the second round and 
increased strongly after the third. 
 
Table 2.4.2. Overview of antibodies’ selection against the L. helveticus MIMLh5 S-layer 
protein. 
 Panning round 
 1 2 3 
 MaxiSorp 
BSA-
blocked 
PolySorp 
BSA-
blocked 
MaxiSorp 
Milk-
blocked 
PolySorp 
Milk-
blocked 
MaxiSorp 
BSA-
blocked 
MaxiSorp 
Milk-
blocked 
PolySorp 
BSA-
blocked 
PolySorp 
Milk-
blocked 
Phages 
applied 
(input)a 
6.48 × 1012 6.48 × 1011 2.58 × 1011 4.20 × 1011 3.42 × 1011 3.42 × 1011 2.3 × 1011 2.30 × 1011 
Phages 
eluted 
(output) 
1.33 × 108 9.30 × 107 2.33 × 106 9.74 × 106 2.27 × 107 1.35 × 108 5.71 × 106 6.86 × 107 
Backgroun
d controlb – – 3.82 × 10
6
 1.08 × 107 6.81 × 106 1.51 × 108 8.54 × 104 3.85 × 105 
Phage 
recovery 
percentage 
0.21 × 10-4 0.14 × 10-4 0.90 × 10-5 2.31 × 10-5 0.66 × 10-4 3.95 × 10-4 2.48 × 10-5 2.98 × 10-4 
Backgroun
db/Output – – 1.64 1.11 0.73 1.12 1.50 × 10
-2
 5.51 × 10-3 
a
 The calculated empirical input. 
b
 In phage selection experiments the background binding during the first panning round is not 
calculated, because the enrichment of specific binders after the first panning round is never 
visible. 
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The decreased background/output ratio and the increased phage recovery percentage (quantity 
of eluted phage divided by quantity of input phage) after the third panning round (in 
comparison with the second one) indicated that clones bound to the S-layer protein were 
enriched after 3 rounds of panning. 
Testing. To screen for binding activity of selected four phage pools (scFv-p3 fusions) to the L. 
helveticus MIMLh5 S-layer protein the dissociation enhanced lanthanide fluoroimmunoasay 
(DELFIA®) was used and time resolved fluorescence (TRF) from Eu3+ was measured (Figure 
2.4.7). 
Figure 2.4.7. Binding of the enriched phage pools (on MaxiSorpTM and PolySorpTM plates) to 
the immobilised S-layer protein after 2nd and 3rd rounds of panning. White columns represent 
time resolved fluorescence values (counts) of polyclonal anti-S-layer-scFv-p3 particles (diluted 
1 : 10000) bound to immobilised S-layer protein of L. helveticus MIMLh5, blocked with BSA or 
milk; and black columns represent values of binding to blocking agent (BSA or milk). Time 
resolved fluorescence counts are presented on a logarithmic scale. 
 
S-layer protein-binding clones were strongly enriched after 3 rounds of panning on both 
surfaces, MaxiSorpTM and PolySorpTM (Figure 2.4.7). These results are in agreement with phage 
count data (Table 2.4.2). 
After the 3rd panning round, both MaxiSorpTM pools and both PolySorpTM pools were similar 
among themselves for the S-layer protein binding. Therefore, individual clones were further 
isolated from one of the MaxiSorpTM and one of the PolySorpTM phage pools: 3rd-Maxi-BSA 
and 3rd-Poly-BSA. 
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2.4.5.3 Cloning and screening for individual binders 
Subcloning. MaxiSorpTM BSA-blocked and PolySorpTM BSA-blocked scFv pools (scFv-p3 
fusions) were subcloned into pLK06H for expression as periplasm-expressed His-tagged PhoA 
(anti-S-layer-scFv-PhoA-6×His) fusions (Figure 2.4.8). 
 
Figure 2.4.8. Cloning scheme to obtain individual anti-S-layer-scFv binders: PhoA fusion. 
 
Single clones of transformants were cultivated in the wells of a microtiter plate and 84 
individual scFv-PhoA-6×His binders were produced. 
 
Screening for the binding activity of individual phage antibodies to purified S-layer 
protein. In order to evaluate the specificity of 84 scFv- PhoA binders for detecting the L. 
helveticus MIMLh5 purified S-layer protein, an AP chromogenic ELISA assay was performed 
on immobilised S-layer protein on MaxiSorpTM plates (Figure 2.4.9). 
Thirty seven individual clones (44 %), in which scFv exhibited the strongest interaction with S-
layer protein, were selected. 
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Screening for the binding activity of monoclonal scFv antibodies to S-layer protein-
containing (Slp+) bacterial cells. A similar AP chromogenic ELISA assay was performed with 
37 selected scFv-PhoA binders in order to evaluate their specificity towards non-purified S-
layer protein present on intact bacterial cells of L. helveticus MIMLh5. To this aim, we 
developed an assay in which antibodies were added to a suspension of bacterial cells (in 
suspension assay) (Figure 2.4.10). 
Figure 2.4.10. Characteristics of individual anti-S-layer protein scFv binders (step 2). White 
columns represent pNPP chromogenic in suspension assay absorbance at 405 nm of 
monoclonal anti-S-layer-scFv-PhoA-6×His particles bound to L. helveticus MIMLh5 cells; 
black columns represent binding to L. delbrueckii subsp. bulgaricus ATCC 11842 (Lb11842; 
Slp–) cells. Antibody selection threshold (as described in chapter 2.3.12) is indicated with a 
horizontal line and an arrow. 
 
Assay buffer (mKAB) and the lysate of E. coli XL1-Blue cells (which do not express any 
binder) were included as negative controls to demonstrate the pNPP background absorbance. 
StrepA G09-scFv and Tropo37-scFv binders that were obtained from pannings with proteins, 
not related to the S-layer protein, were used as negative controls to demonstrate the preliminary 
background binding signal of pNPP chromogenic assay. 
It was found that fifteen out of 37 scFv binders (40.5 %) were specific binders to L. helveticus 
MIMLh5 (Slp+), but not to L. delbrueckii subsp. bulgaricus ATCC 11842 (Slp–, a species 
phylogenetically closely related to L. helveticus, but lacking the S-layer protein). Fourteen of 
them had high relative expression levels 
Finally, in suspension assay was performed with diverse S-layer containing bacterial cells: L. 
helveticus MIMLh5 (contains our analysed S-layer protein), L. helveticus ATCC 15009 (has the 
S-layer protein similar to that of MIMLh5, and diverse from MIMLh5 in only five amino 
acids), L. helveticus SLh02 (harbours the S-layer protein, belonging to the second type of S-
layer proteins, related to that of L. helveticus MIMLh5; Figure 2.4.4), L. acidophilus ATCC 
4356 and NCFM (two identical S-layer proteins, phylogenetically related to that of L. helveticus 
MIMLh5) (Figure 2.4.5). L. delbrueckii subsp. bulgaricus ATCC 11842 is a bacterial species 
phylogenetically related to L. helveticus, but it does not have the S-layer protein (Slp–). Fifteen 
Slp+ bacterial cell-specific scFv binders were analysed (Figure 2.4.11). 
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Figure 2.4.11. Characteristics of individual anti-S-layer protein scFv binders (step 3). White 
columns represent pNPP chromogenic assay absorbance at 405 nm of monoclonal anti-S-layer-
scFv-PhoA-6×His particles bound to L. helveticus MIMLh5 cells; black columns represent 
binding to L. delbrueckii subsp. bulgaricus ATCC 11842 (Slp–) cells; diverse grey columns 
represent absorbance at 405 nm of monoclonal anti-S-layer-scFv-PhoA-6×His particles bound 
to bacterial cells harbouring phylogenetically-related S-layer proteins (Figure 2.4.5). 
 
The assay demonstrated that fourteen scFv antibodies recognised only L. helveticus MIMLh5 
cells. One antibody, anti-S-layer scFv-PhoA-6×His PolyF5, was less specific and recognised 
both, L. helveticus MIMLh5 and L. helveticus ATCC 15009 S-layer proteins present on 
bacterial cells. It is worth noting that binders PolyH4 and PolyH5 had very low background 
binding level. 
 
Sequencing. DNA of the fifteen monoclonal binders, in which anti-S-layer-scFv-PhoA 
exhibited the best interaction with L. helveticus MIMLh5 S-layer protein, was sequenced: 
MaxiA9, B2, B3, B9, B11, C5, C10, C11, D4, D5, PolyE9, G10, H4, H5, F5. Six of them were 
different: PolyH4, PolyH5, PolyF5, MaxiC5, MaxiC11 and a group of ten identical binders 
(MaxiA9, B11, B2, B3, B9, C10, D4, D5, PolyE9, PolyG10) represented by MaxiB9, which 
according specificity to bacterial cells, harbouring phylogenetically-related S-layer proteins, 
seems to show the highest affinity and the highest expression level (Figure 2.4.11). MaxiC5 was 
discarded, because the phagemid formed a concatemer (data not shown). The deduced amino 
acid sequences were aligned with human synthetic scFv (framework scFv gene) (Figure 2.4.11), 
on the basis of which the pEB32x MolBind libraries were constructed (Brockmann et al., 2011). 
The framework gene and anti-S-layer-scFvs differed in the CDR1 and CDR3 regions of both 
heavy and light chains and CDR2 of heavy chain, which corresponds with the phage library 
design rules (Brockmann et al., 2011). The only PolyF5 binder was selected from pEB32x 
MolBind protein-directed library, because it has a tryptophan (W) as the last amino acid in the 
CDR-L3 loop, the fingerprint of this library. Accordingly, the remaining binders were selected 
from pEB32x MolBind hapten-directed library. 
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2.4.5.4 Determination of anti-S-layer-scFv antibodies’ binding specificity 
A more detailed analysis of the anti-S-layer scFvs binding pattern was achieved by determining 
anti-S-layer-scFv binders’ specificity by Western blotting. For this, five selected scFvs 
(MaxiB9, MaxiC11, PolyF5, PolyH5 and PolyH5) were expressed in liquid cultures as 6×His-
tagged PhoA fusions. For denaturing conditions, they were applied as primary antibodies on 
LAB lysates (selected as described above), separated by SDS–PAGE (denaturing conditions) 
and blotted on a PVDF membrane. The binding of scFvs was detected by an anti-His HRP-
conjugate and visualised with a CN/DAB Liquid Substrate System by chromogenic detection 
(Figure 2.4.13). 
 
Figure 2.4.13. Specificity of anti-S-layer scFvs towards purified S-layer protein of L. helveticus 
MIMLh5 and S-layer protein-containing LAB lysates in denaturing conditions as revealed by 
Western blot. The SDS–PAGE gel was stained with Coomassie brilliant blue G-250 to reveal 
the whole protein profile. CN/DAB substrate was used to visualise the binding of scFvs 
(MaxiB9, MaxiC11, PolyF5, PolyH4, PolyH5). Lane 1, protein molecular weight ladder; lane 
2, L. helveticus MIMLh5 purified S-layer protein; lanes 3–7, lysates of Slp+ LAB strains: L. 
helveticus MIMLh5 (lane 3); L. helveticus ATCC 15009 (lane 4); L. helveticus SLh02 (lane 5); 
L. acidophilus ATCC 4356 (lane 6); L. acidophilus NCFM (lane 7); lane 8, lysate of Slp– L. 
delbrueckii subsp. bulgaricus ATCC 11842 strain, used as a negative control. Sharp bands 
revealed by scFvs are indicated by arrows. 
 
The purified S-layer protein from L. helveticus MIMLh5 (lane 2) was separated in the SDS–
PAGE as a single band (Figure 2.4.13). LAB cell lysates were separated into a mixture of bands 
(lanes 3–8), representing the total bacterial protein content. 
2.4 Results and Discussion 
 
73 
Binders MaxiB9, MaxiC11, PolyH4, PolyH5 strongly bound to the purified S-layer protein of 
the L. helveticus MIMLh5 (Figure 2.4.13, lane 2) as well as to the approximately 45 kDa band, 
representing the S-layer protein in the lysate of the MIMLh5 strain (Figure 2.4.13, lane 3). ScFv 
PolyF5 bound not only to the purified S-layer protein of L. helveticus MIMLh5 and MIMLh5 
cell lysate, but also to the lysate of L. helveticus ATCC 15009 (Figure 2.4.13, PolyF5, lane 4). 
This result is in agreement with the data obtained previously with in suspension assay (Figure 
2.4.11). 
All binders (especially MaxiB9, MaxiC11 and PolyH5) showed relatively high background 
binding. It is not surprising, since antibodies, selected in pannings by phage display technology, 
normally do not demonstrate very high binding affinity. To increase the binder’s affinity, the 
subsequent step of affinity maturation is required (Hoogenboom & Chames, 2000; Barderas et 
al., 2008). However, this was not a task of the present study. 
Summarising, the binding specificity of five different anti-S-layer binders was tested by 
Western blotting in denaturing conditions. Four of them, MaxiB9, MaxiC11, PolyH4 and 
PolyH5, were specific to only the denatured S-layer of L. helveticus MIMLh5 strain. PolyF5 
was less specific and recognised the denatured S-layer protein of both, L. helveticus MIMLh5 
and ATCC 15009 strains. 
To test the binding specificity of five different anti-S-layer binders to the S-layer in native 
conditions, anti-S-layer scFv-6×His-tagged PhoA fusions were applied as primary antibodies 
on non-denatured LAB lysates, dot-blotted on a PVDF membrane and visualised as described 
above (Figure 2.4.14). 
 
 
Figure 2.4.14. Specificity of anti-S-layer scFvs towards purified S-layer protein of L. helveticus 
MIMLh5 and S-layer protein-containing LAB lysates in native conditions as revealed by 
Western dot-blot. CN/DAB substrate was used to visualise the binding of scFvs (MaxiB9, 
MaxiC11, PolyF5, PolyH4, PolyH5). 1, protein molecular weight ladder; 2, L. helveticus 
MIMLh5 purified S-layer protein; 3–7, lysates of Slp+ LAB strains: L. helveticus MIMLh5 (dot 
3); L. helveticus ATCC 15009 (dot 4); L. helveticus SLh02 (dot 5); L. acidophilus ATCC 4356 
(dot 6); L. acidophilus NCFM (dot 7); 8, lysate of Slp– L. delbrueckii subsp. bulgaricus ATCC 
11842 strain, used as a negative control. Sharp dots revealed by scFvs are indicated by arrows. 
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MaxiC11, PolyH4 and PolyH5 strongly bound to the L. helveticus MIMLh5 purified S-layer 
protein and to the lysates of L. helveticus MIMLh5 and ATCC 15009. MaxiB9 demonstrated 
high binding to the lysates of all tested LAB strains. This could be justified by the binder’s low 
specificity in native conditions. PolyF5, as in the case of denaturing conditions, was specific to 
both, L. helveticus MIMLh5 and ATCC 15009, S-layer proteins. 
As in the case of denaturing conditions, also in native conditions all binders showed relatively 
high background binding. It is not surprising, taking into account not only the binders’ low 
affinity, but also the presence of other histidine-containing bacterial proteins that exist in the 
intact bacterial protein extract, which is concentrated in one dot (but not fractionated as in the 
case of denaturing conditions). It is worth noting that in the case of PolyH4 binding to the lysate 
of L. delbrueckii subsp. bulgaricus ATCC 11842 strain (Slp–), the dot was almost invisible. 
These results confirm the high specificity of scFv PolyH4 to the S-layer protein of L. helveticus 
MIMLh5. Therefore, this binder was further tested for sensitivity (chapter 2.4.5.5) and used to 
detect the L. helveticus MIMLh5 S-layer protein on Grana Padano cheese samples. 
2.4.5.5 Determination of anti-S-layer-scFv antibodies’ sensitivity 
In order to test the anti-S-layer scFv PolyH4 sensitivity, the L. helveticus MIMLh5 S-layer 
protein detection limit with this antibody was determined. For this reason, different quantities of 
the L. helveticus MIMLh5 S-layer protein solution were spotted on the membrane: 1 µg, 500 
ng, 100 ng, 10 ng, 1 ng, 500 pg, 100 pg, 10 pg, and 1 pg. The anti-S-layer scFv PolyH4 was 
used for Western blotting as primary antibody, and the chromogenic detection was performed as 
described in chapter 2.3.15. The blotogram revealed the presence of the L. helveticus MIMLh5 
S-layer protein in the range of quantities starting from 500 pg – 1 ng (Figure 2.4.15). 
 
Figure 2.4.15. Sensitivity of anti-S-layer scFv 
PolyH4 against different quantities of the L. 
helveticus MIMLh5 S-layer protein. 1, protein 
molecular weight ladder; 2, 1 µg; 3, 500 ng; 4, 
100 ng; 5, 10 ng; 6, 1 ng; 7, 500 pg; 8, 100 pg; 9, 
10 pg; 10, 1 pg of the L. helveticus MIMLh5 S-
layer protein. 
 
This result is in agreement with indirect CN/DAB Liquid Substrate System chromogenic 
detection limit. 
2.4.6 Detection of L. helveticus S-layer protein in Grana Padano samples 
L. helveticus MIMLh5 was isolated from NWS used in the production of Grana Padano, a 
protected-designation-of-origin cheese, produced in specific areas of Northern Italy (Italian 
Presidential Decree, 1955). The monitoring of bacterial population dynamics during Grana 
Padano cheese productions was documented (Zago et al., 2007), and the persistence of L. 
helveticus strains in its NWS and the first maturation phases was described (Gatti et al., 2004; 
Lazzi et al., 2004; Rossetti et al., 2008; Santarelli et al., 2008). However, no information is 
present concerning the fate of the immunologically important S-layer protein of this bacterium 
during the Grana Padano cheese production and ripening process. 
To select the optimal conditions for the S-layer protein extraction from cheese samples, we used 
the NWS, as a sample with the highest probability to possess the largest amounts of L. 
helveticus S-layer protein (Zago et al., 2007). We performed S-layer extraction from NWS with 
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several different reagents: (1) 5 M LiCl (Lortal et al., 1992; Smit et al., 2001), (2) 1 % and 4 % 
SDS at room temperature and boiling (extraction protocol used to obtain total bacterial protein 
extracts; Austin et al., 1990), (3) 5 M and 8 M urea (Podleśny et al., 2011), (4) 6 M guanidine 
hydrochloride (GuHCl, Boot et al., 1993; Sillanpää et al., 2000; Garrote et al., 2004), (5) 
combining 5 M LiCl and 8 M urea, (6) phosphate-buffered saline (PBS). The obtained extracts 
were spotted on the blotting membrane, and the S-layer protein was detected using a single anti-
S-layer scFv PolyH4 as the most specific binder with the lowest background binding as 
revealed previously (Figure 2.4.13 and Figure 2.4.14). Specificity of anti-S-layer scFv PolyH4 
against Grana Padano NWS extracts, obtained after treatment in different conditions, is 
presented in Figure 2.4.16. 
 
 
Figure 2.4.16. Selection of S-layer protein extraction conditions. Specificity of anti-S-layer 
scFv PolyH4 against Grana Padano NWS extracts (A), obtained after treatment in different 
conditions: 1, 5 M LiCl room temperature (R/T), 2, 5 M urea R/T, 3, 1 % SDS R/T, 4, 1 % SDS 
100 °C, 5, 4 % SDS R/T, 6, 4 % SDS 100 °C, 7, PBS R/T, 8, 6 M GuHCl R/T, 9, 5 M LiCl and 8 
M urea R/T, 10, 8 M urea R/T. Purified L. helveticus MIMLh5 S-layer protein (S) was used as 
positive control. Protein molecular weight ladder (L) was used as Western blotting positive 
control. Milk (B) and extraction buffers (C) were used as negative controls. 
 
6 M GuHCl demonstrated too harsh conditions by visibly destroying the blotting membrane. 
SDS extraction gave negative results (Figure 2.4.16A 3–6). After extraction with 5 M LiCl, 5 M 
urea, 5 M LiCl with 8 M urea, and 8 M urea it was possible to visualise the signals (Figure 
2.4.16A 1–2, 9–10). PBS extract gave a signal, but formed a particulate material on the 
membrane (Figure 2.4.16A 7). No detectable signal from the negative controls proved that all 
the observed positive dots must be binding from scFvs, and not unspecific phage particle 
binding (Figure 2.4.16B 1–10). However, the strongest positive signal was obtained with the S-
layer-specific extraction agent, 5 M LiCl (Figure 2.4.16A 1). For this reason, the extraction 
buffer 5 M LiCl was selected to extract the S-layer protein from all selected Grana Padano 
samples. 
NWS, curd and seven “cheese” samples from five Grana Padano cheese maturation phases were 
selected as indicated in chapter 2.3.16. S-layer protein was extracted with 5 M LiCl and the 
extracts were applied on the blotting membrane. Anti-S-layer scFv PolyH4 was used as primary 
antibody for the S-layer protein detection (Figure 2.4.17). 
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Figure 2.4.17. Detection of L. helveticus MIMLh5 
S-layer protein in Grana Padano NWS, curd and 
“cheese” samples with anti-S-layer scFv PolyH4 
binder: 1, NWS, 2, curd, 3 GP-2.0, 4, GP-3.5, 5, 
GP-3.6, 6, GP-4.0, 7-9, GP-5.0 months, 10, 
negative control (milk). 
 
 
Western blot analysis with anti-S-layer scFv PolyH4 binder revealed the presence of L. 
helveticus MIMLh5 S-layer protein in Grana Padano NWS, curd and “cheese” samples from 
maturation phases of 2.0, 3.5, 3.6, 4.0 and 5.0 months (Figure 2.4.17). The most intense dot was 
that of the NWS, as it should contain the highest amount of L. helveticus cells (Zago et al., 
2007). Different dot intensities of 5-month samples could be explained by differences between 
manufacturer the samples were taken from. 
These results showed promising applications of anti-S-layer scFv PolyH4 binder for the 
detection of immunologically important L. helveticus S-layer protein at nanogram quantities in 
Grana Padano cheese and other food matrices. 
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2.5 CONCLUSIONS 
According to the tasks described in the chapter 2.2, the following conclusions were drawn: 
1. Efficient extraction protocol was set up to obtain pure extracts of L. helveticus 
MIMLh5 S-layer protein. 
2. L. helveticus MIMLh5 S-layer protein mass was found to be 43853 Da. 
3. Phage display technology was successfully employed to select the L. helveticus 
MIMLh5 S-layer protein-specific binders. 
4. Five different anti-S-layer scFv binders were selected from phage display libraries. 
Four of them, MaxiB9, MaxiC11, PolyH4 and PolyH5, were specific to only the S-
layer of L. helveticus MIMLh5 strain. PolyF5 recognised the S-layer protein of L. 
helveticus MIMLh5 and ATCC 15009 strains. 
5. On this basis, an assay for the detection of L. helveticus MIMLh5 S-layer protein in 
Grana Padano cheese was developed using anti-S-layer scFv PolyH4 binder. 
The expressed scFvs were applied in Western blotting analysis and showed promising 
application in detection of immunologically important L. helveticus MIMLh5 S-layer protein at 
nanogram quantities in Grana Padano cheese and other food matrices. 
A following study is now in progress to identify the presence and the immunomodulatory 
activity of the S-layer protein in Grana Padano cheese ripened more than 5 months and in Grana 
Padano cheese submitted to simulated gastrointestinal digestion. 
 
2.6 References 
 
78 
2.6 REFERENCES 
1. Agave BioSystems, S-Layer Catalog. www.agavebio.com (accessed: 26/08/11). 
2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ, 1990, Basic local alignment 
search tool. J Mol Biol 215:403-410. 
3. Austin JW, Stewart M, Murray RG, 1990, Structural and chemical characterization of 
the S layer of a Pseudomonas-like bacterium. J Bacteriol 172:808-817. 
4. Åvall-Jääskeläinen S, Palva A, 2005, Lactobacillus surface layers and their 
applications. FEMS Microbiol Rev 29:511-529. 
5. Babel I, Barderas R, Pelaez-Garcia A, Casal JI, 2011, Antibodies on demand: a fast 
method for the production of human scFvs with minimal amounts of antigen. BMC 
Biotechnol 11:61. 
6. Barderas R, Desmet J, Timmerman P, Meloen R, Casal JI, 2008, Affinity maturation 
of antibodies assisted by in silico modeling. Proc Natl Acad Sci U S A 105:9029-9034. 
7. Beganović J, Frece J, Kos B, Leboš Pavunc A, Habjanič K, Šušković J, 2011, 
Functionality of the S-layer protein from the probiotic strain Lactobacillus helveticus 
M92. Antonie Van Leeuwenhoek 100:43-53. 
8. Benhar I, 2001, Biotechnological applications of phage and cell display. Biotechnol 
Adv 19:1-33. 
9. Boot HJ, Kolen CP, van Noort JM, Pouwels PH, 1993, S-layer protein of Lactobacillus 
acidophilus ATCC 4356: purification, expression in Escherichia coli, and nucleotide 
sequence of the corresponding gene. J Bacteriol 175:6089-6096. 
10. Bradbury AR, Sidhu S, Dubel S, McCafferty J, 2011, Beyond natural antibodies: the 
power of in vitro display technologies. Nat Biotechnol 29:245-254. 
11. Brockmann EC, Akter S, Savukoski T, Huovinen T, Lehmusvuori A, Leivo J, 
Saavalainen O, Azhayev A, Lövgren T, Hellman J, Lamminmäki U, 2011, Synthetic 
single-framework antibody library integrated with rapid affinity maturation by VL 
shuffling. Protein Eng Des Sel 24:691-700. 
12. Brockmann EC, Evolution of Bioaffinity Reagents by Phage Display. PhD Thesis, 
University of Turku, Turku, Finland, 2010. 
13. Broders O, Breitling F, Dubel S, 2003, Hyperphage. Improving antibody presentation 
in phage display. Methods Mol Biol 205:295-302. 
14. Carmen S, Jermutus L, 2002, Concepts in antibody phage display. Brief Funct 
Genomic Proteomic 1:189-203. 
15. Clackson T, Hoogenboom HR, Griffiths AD, Winter G, 1991, Making antibody 
fragments using phage display libraries. Nature 352:624-628. 
16. Consorzio Tutela Grana Padano, www.granapadano.it (accessed 26/08/11). 
17. EFSA, Qualified Presumption of Safety of Micro-organisms in Food and Feed. EFSA 
Scientific Colloquium Summary Report, Brussels, Belgium, 13-14/12/2004. 
18. Efthymiou C, Hansen PA, 1962, An antigenic analysis of Lactobacillus acidophilus. J 
Infect Dis 110:258-267. 
2.6 References 
 
79 
19. Garrote GL, Delfederico L, Bibiloni R, Abraham AG, Perez PF, Semorile L, De 
Antoni GL, 2004, Lactobacilli isolated from kefir grains: evidence of the presence of 
S-layer proteins. J Dairy Res 71:222-230. 
20. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A, 
Protein Identification and Analysis Tools on the ExPASy Server. In The Proteomics 
Protocols Handbook, Walker JM, ed., Humana Press 2005, pp. 571-607. 
21. Gatti M, Rossetti L, Fornasari ME, Lazzi C, Giraffa G, Neviani E, 2005, Heterogeneity 
of putative surface layer proteins in Lactobacillus helveticus. Appl Environ Microbiol 
71:7582-7588. 
22. Gatti M, Trivisano C, Fabrizi E, Neviani E, Gardini F, 2004, Biodiversity among 
Lactobacillus helveticus strains isolated from different natural whey starter cultures as 
revealed by classification trees. Appl Environ Microbiol 70:182-190. 
23. Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Zanoni I, Stuknyte M, Granucci F, 
Karp M, Mora D, 2010, A dairy bacterium displays in vitro probiotic properties for the 
pharyngeal mucosa by antagonizing group A streptococci and modulating the immune 
response. Infect Immun 78:4734-4743. 
24. Hollmann A, Delfederico L, Miyoshi A, Disalvo EA, De Antoni G, Semorile L, 
Azevedo V, 2010, S-layer proteins from lactobacilli as vaccine delivery systems. Int J 
Microbiol Res 2:30-43. 
25. Hoogenboom HR, Chames P, 2000, Natural and designer binding sites made by phage 
display technology. Immunol Today 21:371-378. 
26. Horejs C, Mitra MK, Pum D, Sleytr UB, Muthukumar M, 2011, Monte Carlo study of 
the molecular mechanisms of surface-layer protein self-assembly. J Chem Phys 
134:125103. 
27. Italian Presidential Decree, Riconoscimento delle denominazioni circa i metodi di 
lavorazione, caratteristiche merceologiche e zone di produzione dei formaggi 
[Certification of Cheeses According to the Production Technologies, the Chemical 
Characteristics and the Production Area]. DPR n 1269, 30/10/1955. 
28. Johnson-Henry KC, Hagen KE, Gordonpour M, Tompkins TA, Sherman PM, 2007, 
Surface-layer protein extracts from Lactobacillus helveticus inhibit 
enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell 
Microbiol 9:356-367. 
29. Kehoe JW, Kay BK, 2005, Filamentous phage display in the new millennium. 
Chemical Rev 105:4056-4072. 
30. Knappik A, Ge L, Honegger A, Pack P, Fischer M, Wellnhofer G, Hoess A, Wolle J, 
Pluckthun A, Virnekas B, 2000, Fully synthetic human combinatorial antibody 
libraries (HuCAL) based on modular consensus frameworks and CDRs randomized 
with trinucleotides. J Mol Biol 296:57-86. 
31. Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, Molle D, 
Lortal S, Altermann E, Klaenhammer TR, van Kooyk Y, 2008, S layer protein A of 
Lactobacillus acidophilus NCFM regulates immature dendritic cell and T cell 
functions. Proc Natl Acad Sci U S A 105:19474-19479. 
2.6 References 
 
80 
32. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, 
Plückthun A, 1997, Reliable cloning of functional antibody variable domains from 
hybridomas and spleen cell repertoires employing a reengineered phage display 
system. J Immunol Methods 201:35-55. 
33. Lazzi C, Rossetti L, Zago M, Neviani E, Giraffa G, 2004, Evaluation of bacterial 
communities belonging to natural whey starters for Grana Padano cheese by length 
heterogeneity-PCR. J Appl Microbiol 96:481-490. 
34. Lortal S, Cheeses made with Thermophilic Lactic Starters. In Handbook of Food and 
Beverage Fermentation Technology, Hui YH, Meunier-Goddik L, Hansen ÖS, 
Josephsen J, Nip WK, Stanfield PS, Toldra F, eds., CRC Press 2004, pp. 340-358. 
35. Lortal S, Vanheijenoort J, Gruber K, Sleytr UB, 1992, S-Layer of Lactobacillus 
helveticus ATCC 12046: Isolation, Chemical Characterization and Re-Formation after 
Extraction with Lithium Chloride. J Gen Microbiol 138:611-618. 
36. Messner P, Allmaier G, Schaffer C, Wugeditsch T, Lortal S, Konig H, Niemetz R, 
Dorner M, 1997, Biochemistry of S-layers. FEMS Microbiol Rev 20:25-46. 
37. Mobili P, Gerbino E, Tymczyszyn EE, Gómez-Zavaglia A, S-layers in lactobacilli: 
structural characteristics and putative role in surface and probiotic properties of whole 
bacteria. In Current Research, Technology and Education Topics in Applied 
Microbiology and Microbial Biotechnology, Méndez-Vilas A, ed., Formatex Research 
Center 2010, pp. 1224-1234. 
38. Orla-Jensen S, The Lactic Acid Bacteria. Host & Son 1919. 
39. Paschke M, 2006, Phage display systems and their applications. Appl Microbiol 
Biotechnol 70:2-11. 
40. Podleśny M, Jarocki P, Komon E, Glibowska A, Targonski Z, 2011, LC-MS/MS 
analysis of surface layer proteins as a useful method for the identification of 
lactobacilli from the Lactobacillus acidophilus group. J Microbiol Biotechnol 21:421-
429. 
41. Pum D, Sára M, Schuster B, Sleytr UB, Bacterial Surface Layer Proteins: a Simple but 
Versatile Biological Self-assembly System in Nature. In Nanotechnology: Science and 
Computation, Chen J, Jonoska N, Rozenberg G, eds., Springer 2006, pp. 277-290. 
42. Rossetti L, Fornasari ME, Gatti M, Lazzi C, Neviani E, Giraffa G, 2008, Grana Padano 
cheese whey starters: microbial composition and strain distribution. Int J Food 
Microbiol 127:168-171. 
43. Sambrook J, Russell DW, Molecular cloning: a laboratory manual. Cold Spring Harbor 
Laboratory Press, 3rd Edition, 2001. 
44. Sanders ME, Klaenhammer TR, 2001, Invited review: the scientific basis of 
Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 84:319-331. 
45. Sanger F, Nicklen S, Coulson AR, 1977, DNA sequencing with chain-terminating 
inhibitors. Proc Natl Acad Sci U S A. 74:5463-5467. 
46. Santarelli M, Gatti M, Lazzi C, Bernini V, Zapparoli GA, Neviani E, 2008, Whey 
starter for Grana Padano cheese: effect of technological parameters on viability and 
composition of the microbial community. J Dairy Sci 91:883-891. 
2.6 References 
 
81 
47. Sára M, Sleytr UB, 2000, S-layer proteins. J Bacteriol 182:859-868. 
48. Schuster B, Sleytr UB, 2009, Composite S-layer lipid structures. J Struct Biol 168:207-
216. 
49. Sillanpää J, Martinez B, Antikainen J, Toba T, Kalkkinen N, Tankka S, Lounatmaa K, 
Keranen J, Hook M, Westerlund-Wikstrom B, Pouwels PH, Korhonen TK, 2000, 
Characterization of the collagen-binding S-layer protein CbsA of Lactobacillus 
crispatus. J Bacteriol 182:6440-6450. 
50. Sleytr UB, 1997, Basic and applied S-layer research: An overview. FEMS Microbiol 
Rev 20:5-12. 
51. Sleytr UB, Beveridge TJ, 1999, Bacterial S-layers. Trends Microbiol 7:253-260. 
52. Sleytr UB, Gyorvary E, Pum D, 2003, Crystallization of S-layer protein lattices on 
surfaces and interfaces. Progr Org Coat 47:279-287. 
53. Smit E, Oling F, Demel R, Martinez B, Pouwels PH, 2001, The S-layer protein of 
Lactobacillus acidophilus ATCC 4356: identification and characterisation of domains 
responsible for S-protein assembly and cell wall binding. J Mol Biol 305:245-257. 
54. Smith GP, 1985, Filamentous fusion phage: novel expression vectors that display 
cloned antigens on the virion surface. Science 228:1315-1317. 
55. Smith J, Kontermann RE, Embleton J, Kumar S, 2005, Antibody phage display 
technologies with special reference to angiogenesis. FASEB J 19:331-341. 
56. Smith KA, Nelson PN, Warren P, Astley SJ, Murray PG, Greenman J, 2004, 
Demystified... recombinant antibodies. J Clin Pathol 57:912-917. 
57. Söderlind E, Strandberg L, Jirholt P, Kobayashi N, Alexeiva V, Aberg AM, Nilsson A, 
Jansson B, Ohlin M, Wingren C, Danielsson L, Carlsson R, Borrebaeck CA, 2000, 
Recombining germline-derived CDR sequences for creating diverse single-framework 
antibody libraries. Nat Biotechnol 18:852-856. 
58. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S, 2011, MEGA5: 
molecular evolutionary genetics analysis using maximum likelihood, evolutionary 
distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739. 
59. Tuohy KM, Probert HM, Smejkal CW, Gibson GR, 2003, Using probiotics and 
prebiotics to improve gut health. Drug Discov Today 8:692-700. 
60. Willats WG, 2002, Phage display: practicalities and prospects. Plant Mol Biol 50:837-
854. 
61. Zago M, Fornasari ME, Rossetti L, Bonvini B, Scano L, Carminati D, Giraffa G, 2007, 
Population dynamics of lactobacilli in Grana cheese. Ann Microbiol 57:349-353. 
 
Acknowledgements 
 
82 
ACKNOWLEDGEMENTS 
This thesis work was carried out between the years 2009 – 2011 in the Department of Food 
Science and Technology at the University of Milan in Italy. Financial support from the Graduate 
School in Molecular Sciences and Plant, Food and Environmental Biotechnology is gratefully 
acknowledged. 
I wish to sincerely thank my supervisors, prof. Ivano De Noni, dr. Simone Guglielmetti and prof. 
Diego Mora, who introduced me to interesting scientific problems and have guided me through 
this thesis work. I am grateful to Ivano for his enthusiasm towards the undiscovered areas, for his 
precise insights and comments, for uncovering the unknown world of analytical techniques, for 
the everyday lectures of self-confidence, for teaching me to speak the correct Italian and for 
always being in time! I thank Diego for giving me the idea to do this PhD, for the suggestions 
that helped to cool down and inspired. I appreciate the valuable help of Simone in lab and on-line 
in the scientific and spiritual areas and especially in the field of immunology. I thank him for 
opening the doors for the Finnish collaboration. I also thank all my three advisors for constant 
and continuous scientific discussions as well as for precious suggestions on our publications and 
insightful comments on this thesis manuscript, which helped to improve it. 
I appreciate the contribution of my special irreplaceable collaborators: Mario Minuzzo, Stefania 
Arioli, Valentina Taverniti and Nano Sodomita, who were always in time and in the right place, 
when it was inevitably necessary. 
A special thanks goes to dr. Urpo Lamminmäki and to all VAM people from the Department of 
Biotechnology at the University of Turku in Finland. Upi, thanks for hosting me in your group 
and for unveiling me the beautiful world of the phage display! I am very grateful to Eeva for 
following my every single day for entire five months and saving me from desperate situations 
when it was really necessary. I owe my gratitude to Tuomas for fruitful scientific discussions. 
I warmly thank the milk people for the scientific assistance and for friendly attitude: prof. Luisa 
Pellegrino, Stefano, John, Veronica, Fabio, Daniela F. and Amalia. 
I appreciate the invaluable help of dr. Davide Ticozzi and dr. Simona Scarpella from “Waters” 
for introducing me and guiding me inside the field of mass spectrometry. 
I would like to acknowledge dr. Angelo Stroppa from the Consorzio Tutela Grana Padano for 
providing us with Grana Padano samples and dr. Guillaume Dalmasso from Emory University 
School of Medicine (Atlanta, GA, USA) for providing with detailed experimental conditions for 
KPV anti-inflammatory response in Caco-2 cells. 
I have to mention my friends and dear people outside the lab and this country: Vaiva, Danguolė, 
Andrej, Liuda ir Muziukė, Alina, Vaida, Aida, Romas, Andrius, Arūnas, Rasa, Jovita, Julija, 
Juozas, Džiuga, Tadas, Lina, Audrius ir Inga bei visa smagi Šimonėlių kompanija, Mauro, Moira, 
Nadia, Manu, Michy, Ale, Jelena, Marta, Silvana, Teresio, Cristina, Livio, Lorenzo and Lapo 
who supported and still support me and resist with my rare e-mails, visits and conversations. 
I thank my great family. Dėkoju visai savo gausiai šeimai: Mamai, Tėčiui, Justinai, Gediminui, 
Močiutei ir Babai, Dainiui ir Lukai, Eglei ir Ugniui, tetulytėms Rūtai ir Tučiui, Liudui, Gintui ir 
Gailei, Kurmei ir Aristoteliui bei visiems kitiems artimiesiems, kurių čia nepaminėjau. Ačiū, kad 
mane palaikėt ir palaikot kiekvieną dieną, džiaugiatės visus šiuos metus tik retokais mano vizitais 
namo ir pakenčiat mano valandinius telefoninius pokalbius. 
Ačiū Jonui: už viską, kas tikrai nesutelpa į šias eilutes ir į visą šį kūrinį... 
 
Milan, December 2011 
Appendix 1. Copies of Abstracts of Papers, Oral Communications and Posters 
 
83 
APPENDIX 1. COPIES OF ABSTRACTS OF PAPERS, ORAL 
COMMUNICATIONS AND POSTERS 
1. Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Stuknyte M, Karp M, Mora D, 
2010, Oral bacteria as potential probiotics for the pharyngeal mucosa. Appl Environ 
Microbiol 76:3948-3958. 
2. Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Zanoni I, Stuknyte M, Granucci F, 
Karp M, Mora D, 2010, A dairy bacterium displays in vitro probiotic properties for the 
pharyngeal mucosa by antagonizing group A streptococci and modulating the immune 
response. Infect Immun 78: 4734-4743. 
3. Stuknyte M, De Noni I, Guglielmetti S, Minuzzo M, Mora D, 2011, Potential 
immunomodulatory activity of bovine casein hydrolysates produced after digestion 
with proteinases of lactic acid bacteria. Int Dairy J 21:763-769. 
4. Stuknyte M, Brockmann E-C, Huovinen T, Taverniti V, Guglielmetti S, Mora D, De 
Noni I, Lamminmäki U, manuscript, Selection of a Single-Chain Variable Fragment 
Antibody against Lactobacillus helveticus MIMLh5 S-layer Protein from Phage 
Displayed Libraries. 
 
5. Stuknyte M, Development of bioprocesses for the production of food protein 
hydrolysates containing bioactive peptides. In Proceedings of the 14th Workshop on the 
Developments in the Italian PhD Research on Food Science Technology and 
Biotechnology, Oristano, Italy, 16-18 September, 2009, pp. 446-447. 
6. Stuknyte M, Development of bioprocesses for the production of food protein 
hydrolysates containing bioactive peptides. In Proceedings of the 15th Workshop on the 
Development in the Italian PhD Research on Food Science Technology and 
Biotechnology, Portici, Italy, 15-17 September, 2010, pp. 299-300. 
7. Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Stuknyte M, Zanoni I, Granucci F, 
Karp M, Mora D, Lactic acid bacteria as potential probiotics for the pharyngeal mucosa. In 
Abstracts of the 10th Symposium on Lactic Acid Bacteria, Egmond aan Zee, The 
Netherlands, 28 August – 1 September, 2011. 
8. Stuknyte M, Immunomodulatory activity of bovine casein hydrolysates produced after 
digestion with proteinases of lactic acid bacteria. In Proceedings of the 16th Workshop 
on the Developments in the Italian PhD Research on Food Science Technology and 
Biotechnology, Lodi, Italy, 21-23 September, 2011, pp. 181-185. 
9. Stuknyte M, Brockmann E-C, Huovinen T, Taverniti V, Guglielmetti S, Mora D, De 
Noni I, Lamminmäki U, Lactobacillus helveticus S-layer protein specific binders from 
antibody libraries. In Book of Abstracts of The 4th Interdepartmental Twinning 
Symposium, Tammela, Finland, 28 September – 2 October, 2011, p. 17. 
Appendix 1. Copies of Abstracts of Papers, Oral Communications and Posters 
 
84 
 
Appendix 1. Copies of Abstracts of Papers, Oral Communications and Posters 
 
85 
Appendix 1. Copies of Abstracts of Papers, Oral Communications and Posters 
 
86 
Appendix 1. Copies of Abstracts of Papers, Oral Communications and Posters 
 
87 
14th Workshop on the Developments in the Italian PhD Research on Food Science 
Technology and Biotechnology, 16-18 September, 2009 (Oristano, Italy) 
 
Development of bioprocesses for the production of food protein hydrolysates containing 
bioactive peptides 
 
Milda Stuknyte 
 
The PhD thesis research project is aimed at development of bioprocesses for the production of 
food protein hydrolysates (FPHs) containing peptides with specific biological activities by 
exploiting the activity of Cell Envelope-associated Proteinases (CEP) of food-grade bacteria, in 
particular of lactic acid bacteria (LAB). The final object is the definition of completely food-
grade bioprocesses, transferable to the industrial level and addressed to preparation of FPHs, 
which could be used as ingredients in functional foods. 
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15th Workshop on the Development in the Italian PhD Research on Food Science 
Technology and Biotechnology, 15-17 September, 2010 (Portici, Italy) 
 
Development of bioprocesses for the production of food protein hydrolysates containing 
bioactive peptides 
 
Milda Stuknyte 
 
The first two activities of the PhD thesis project are described. Firstly, we performed the 
selection of lactic acid bacteria by screening bacterial cell envelope-associated proteinases 
(CEPs) at the genetic level as well as by testing the proteolytic activity on milk caseins. 
Moreover, fractionation of casein hydrolysates (CHs) by means of high-performance liquid 
chromatography (HPLC) was performed. Secondly, we developed a protocol for the in vitro 
biological analysis of CHs, addressed to determine their immunomodulatory activity by using a 
luciferase reporter gene system. This system is based on a nuclear factor kappa B (NF-κB)-
inducible reporter plasmid, pNiFty2-Luc, in human colonic adenocarcinoma cells Caco-2. 
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10th Symposium on Lactic Acid Bacteria, 28 August – 1 September, 2011 (Egmond aan 
Zee, The Netherlands) 
 
Lactic acid bacteria as potential probiotics for the pharyngeal mucosa 
 
Guglielmetti S, Taverniti V, Minuzzo M, Arioli S, Stuknyte M, Zanoni I, Granucci F, Karp M, 
Mora D 
 
The probiotic approach represents an alternative strategy in the prevention and treatment of 
infections in those body sites where the microbiota plays a role in the maintenance of 
physiological homeostasis. In this context, we evaluated in vitro the potential abilities of oral, 
probiotic and dairy bacteria in controlling Streptococcus pyogenes infections at the pharyngeal 
level. Initially, we analysed the bacterial adhesion on FaDu hypopharyngeal carcinoma cells 
and the ability to antagonize S. pyogenes on FaDu layer and HaCat keratinocytes. Due to their 
promising adhesive and antagonistic features, we studied the oral isolate Streptococcus 
salivarius ST3 and the dairy strain Lactobacillus helveticus MIMLh5 also through 
immunological in vitro experiments. We performed the quantification of several cytokines and 
the measurement of NF-κB activation in FaDu cells. Strain ST3 significantly increased NF-κB 
activation at baseline, while it had an opposite effect when FaDu cells were co-stimulated with 
IL-1β. In addition, ST3 biased cytokines production at baseline (reduction of IL-1β and TNFα, 
increase of MIP-1β and GM-CSF) and after IL-1β-induction (reduction on IL-6 and IL-8). 
MIMLh5 efficiently reduced the induction of IL-6, IL-8 and TNFα in a dose-dependent 
manner. After stimulating with IL-1β, active NF-κB was still markedly lowered. Nevertheless, 
we observed an increased secretion of IL-6, IFN-γ and GM-CSF under these conditions. In 
addition, MIMLh5 increased the GM-CSF/G-CSF ratio. This is compatible with a switch of the 
immune response towards a TH1 pathway, as supported by our observation that MIMLh5, once 
in contact with bone marrow derived dendritic cells, triggered the secretion of TNFα and IL-2. 
In conclusion, we propose ST3 and MIMLh5 as a potential probiotic bacteria for the human 
pharynx, with promising antagonistic and immunomodulatory properties. 
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16th Workshop on the Developments in the Italian PhD Research on Food Science 
Technology and Biotechnology, 21-23 September, 2011 (Lodi, Italy) 
 
Immunomodulatory activity of bovine casein hydrolysates produced after digestion with 
proteinases of lactic acid bacteria 
 
Milda Stuknytė 
 
This report presents the results of the first PhD thesis topic, which dealt with the investigation 
of immunomodulatory activity of bovine casein hydrolysates (CHs), produced after digestion 
with proteinases of lactic acid bacteria. The study demonstrated that the 3 kDa-ultrafiltered 
CHs, produced after digestion with proteinases of Lactobacillus acidophilus ATCC 4356 and 
Lactococcus lactis subsp. lactis GR5, significantly decreased in vitro the basal NF-κB activity 
in intestinal epithelial-like Caco-2 cells, demonstrating immunomodulatory activity. In the case 
of L. helveticus MIMLh5, the immunomodulatory activity was likely due to the bacterial cell 
components present in the whole CH. 
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The 4th Interdepartmental Twinning Symposium, 28 September – 2 October, 2011 
(Tammela, Finland) 
 
Lactobacillus helveticus MIMLh5 S-layer protein-specific binders from antibody libraries 
 
Stuknyte M, Brockmann E, Huovinen T, Taverniti V, Guglielmetti S, Mora D, De Noni I, 
Lamminmäki U 
 
Many strains of Lactobacillus helveticus have been characterised as probiotics. These strains 
were reported to exert health benefits such as protection against infection, e.g. by modulating 
the immune system. L. helveticus MIMLh5, isolated from Grana Padano cheese natural whey 
starter, was proposed as a potential probiotic bacterium for the human pharynx with promising 
antagonistic and immunomodulatory properties (Guglielmetti et al., 2010). The surface layer (S-
layer) protein was identified as being involved in the immunomodulatory properties of L. 
helveticus strains M92 (Beganović et al., 2011), MIMLh5 (Taverniti et al., manuscript in 
preparation). 
Antibodies constitute a powerful tool to study protein function, protein localisation and protein-
protein interactions, as well as for diagnostic and therapeutic purposes. Single-chain variable 
fragment antibodies (scFvs) have considerable potential for the immunological detection of 
small molecules, as well as proteins, in localisation of bacterial surface structures (Bradbury et 
al., 2011). In this study, a mix of two large human synthetic phage displayed libraries, protein-
directed (Brockmann et al., 2011) and hapten-directed, was used to select scFvs against L. 
helveticus MIMLh5 S-layer protein. After three rounds of panning, four monoclonal scFvs 
capable of binding with the L. helveticus MIMLh5 S-layer protein and one capable of binding 
also with the S-layer protein of L. helveticus ATCC 15009, which is different only in five amino 
acids, were obtained. All five identified novel anti-S-layer scFvs were expressed in Escherichia 
coli XL1-Blue as alkaline phosphatase fusions (Krebber et al., 1997). ScFv-PolyH4 was used to 
develop an assay, based on Western blot analysis, for detection of the S-layer protein in Grana 
Padano cheese ripened for 2-5 months. These results showed promising applications of the 
scFv-PolyH4 for detecting immunologically important S-layer protein of L. helveticus in this 
cheese and in other food matrices and underlined the high value of the utilised phage display 
libraries for obtaining the extremely specific scFvs. 
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